TARGETING PSEUDOTYPED RETROVIRAL VECTORS

Inventors: Irvin S.Y. Chen, Palos Verdes Estates, CA (US); Kouki Morizono, Los Angeles, CA (US)

Correspondence Address:
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER, EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834 (US)

Assignee: Regents of the University of California,

Appl. No.: 11/628,586
PCT Filed: Jun. 3, 2005
PCT No.: PCT/US05/19624
§ 371 (c)(1), (2), (4) Date: Aug. 28, 2007

Related U.S. Application Data
Provisional application No. 60/577,248, filed on Jun. 3, 2004.

Publication Classification
Int. Cl.
A61K 31/70 (2006.01)
C12N 15/00 (2006.01)
C12N 5/06 (2006.01)
C12Q 1/68 (2006.01)
A61P 25/00 (2006.01)
C12P 19/34 (2006.01)
C12N 15/87 (2006.01)

U.S. Cl. ....... 514/44; 435/320.1; 435/325; 435/91.4; 435/455; 435/6

ABSTRACT
The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope.

a) HE staining
b) Staining of EGFP
c) Staining of melanoma antigen S-100
d) HE staining
Fig. 3

TRIPGF (ZZ SINDBIS)

TRIPGF (SINDBIS)

TRIPGF (VSV-G)

% of EGFP positive cells
Fig. 4

60aa 70aa 130aa

E3 E2 ZZ

R1 R2 R3 R4 R5

m1 m2 m3 m4 m5 m6 m7 m8 m9

Mutants of each domain

Domains

439aa

55aa
| Injection | Virus | Cell | Antibody | Vector expression | Tumor location (Cobra)
|-----------|-------|------|----------|-------------------|-----------------------
| No        | No    | Injected | No | No | No |
| Control Antibody | Injected | Anti P-Glycoprotein | p/s/cm² | No |
| Anti P-Glycoprotein | Injected | Anti P-Glycoprotein | | | |
FIGURE 8

Nucleic acid sequence encoding ZZSINDBUS

ATGGCTGTCGCGACACACTGTCGACGCGCAATGTTGTCTCCTGGGAAATGTGACCTTCCATGCGACCCTGCGCC
ACATGCTGATACCGGAAACCTCTGCGACCTGCTCGGCTGGAAGAGCTAGGACATGAGGCTACGATAGTACC
CTGCTCAATGCAACTGCTGTTGGCGTGATGCCTGTCTGCGAAGCAAAAGAAAGACATGACTGAAGTGGATCAGT
AGCCCTCTCTGCGATCGTTACGCTGACGCCCGAAGGGGAAACTGACGCTGCTGCTGCTGCTGCTGCTGCTGCT
TGAGAAGACCGGAGGAGGGATAGCTGTCTGCTGCTGCTGCTGCTGCTG
ACCTAGCAGCCACGACTCACTACTGACAGCTTCTTCGAGACTACATGCGATCCGCTGATCGAGAGCTACG
CCTCAGGGGACACGCTGTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
AACACTAGCTTCTGGGAGGAGCTACGCTTCTGCAGATGAGTGAGTGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
Nucleic acid sequence encoding m168

ATGGGCGTCCGACGCACACTGTGGTACGGAATGTGTTGTCCTGCGGAAATGTGATGCTCCATGCGACCGCCGCCC
ACATGCTCATACCGCGAAACCTCTCCAGACCCCTCCGACCTTTAGGAGAATGTGACGACATGAACTGACATGCGAATG
CTGCTCTGATTTCATGCGGCTGACCTGCTGCTGCTGATGGCTGATGCTGATGCTGATGCTGATGCTGATGCTGATG
GGGCCAGATCTCGGAGCTCCCGCAGCATGTGGTCCCTGCCCTGCCCTGCCCTGCCCTGCCCTGCCCTGCCCTG
TCAGATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT
GTGCAGTGACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG
ATTAGCGACCTCGAGGAGGCTGTGGAAGGCTCTGTACACAGAAGGAGTCACCTGCTCCCAAAAACTCCCTCCAGG
AGGACGACGAGGTTTGGATCCTGACGGTGTACCGAGCTGGAACTCGAGCTGGAACTCGAGCTGGAACTCGAGCTG
GGCCAGAACGAGCAAAAAATGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
GCAACAGCAGGGCTACAGTCACATAGCGACAGGCAGCCAGGCTTATACCTACCCTTGAGAAGACTAGT
GGAGAACTTGCGAATGCCCAAGCAGGAAACATGATGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
ACCCGGGATGTTGATGACAGCCGCTCCGTATGACTCCTGCAGCCGATAGTTTGCCCGGCTCGATC
Figure 10

a) HE staining

- Terminal bronchiole
- Micrometastasis
- Alveoli

b) Staining of EGFP

c) Staining of melanoma antigen S-100

d) HE staining
Figure 11
**Figure 12**

(Description of the figure: a) Mac-1 negative and Mac-1 positive regions are shown with a histogram. b) Fluorescence-activated cell sorting (FACS) analysis with FL2 (EGFP) and Uninfected, FUGW (VSV-G), and FUGW (m168) + Anti-P-Gp categories. The graph shows percentage labels: Uninfected (<0.01%), FUGW (VSV-G) (0.06% to 8.52%), and FUGW (m168) + Anti-P-Gp (<0.01% to 0.21%).)
Figure 13A

- No infection
- FUhlucW (VSV-G)
- FUhlucW (m168) control antibody
- FUhlucW (m168) Anti-P-glycoprotein

Legend: p/s/cm²/sr
<table>
<thead>
<tr>
<th>Condition</th>
<th>Lung</th>
<th>Heart</th>
<th>Liver</th>
<th>Spleen</th>
<th>Kidney</th>
<th>Ovary</th>
</tr>
</thead>
<tbody>
<tr>
<td>FUH LucW (m168) control antibody</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
</tbody>
</table>

**Figure 13B**
Figure 14

[Diagram showing flow cytometry results for LNCaP and LPSCA4 cells with fluorescence intensity plots under different conditions: no Ig, α HLA, and 1G8.]
Figure 15
Figure 16

No Ab

Anti-TfR

m168

2.2

0.04%

1.52%

5.94%

49.36%

EGFP
TARGETING PSEUDOTYPED RETROVIRAL VECTORS
CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 60/577,248, filed Jun. 3, 2004, the disclosure of which is hereby incorporated herein by reference in its entirety for all purposes.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant Nos. 5R01 DK54912-06 and 5R01AI39975-01, awarded by the National Institutes of Health. The Government has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates to lentiviral vectors pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope.

BACKGROUND OF THE INVENTION

Clinically effective gene therapy protocols for various diseases would ideally utilize protocols for efficient and specific targeting of therapeutic genes to affected cells while maintaining stable transduction and long term expression. This would be accomplished by direct injection into the bloodstream followed by homing of the vector to the desired target cells or organs. Thus, there have been many attempts to develop targeted gene transduction systems based upon various viral vectors. Adenovirus and adenovirus-associated virus vectors have been used in targeted gene delivery strategies because of their simple binding and entry mechanisms. (Nicklin and Baker, Curr Gene Ther. 2, 273-293 (2002)) Although these vectors have been used successfully in vitro, for targeting to specific cells, their usefulness in vivo has been limited by their natural tropism (Muller et al., Nat. Biotechnol. 21, 1040-1046 (2003)), especially to liver cells (Martin et al., Mol. Ther. 8, 485-494 (2003)).

Oncoretroviral- and lentiviral-based vectors have several properties that make them ideal for use in gene therapy (Sandrin et al., Curr. Top. Microbiol. Immunol. 281: 137-78, 137-178 (2003)). Efficient integration of retroviral DNA into the host genome enables stable long-term transgene expression. Unlike oncolentiviral vectors, lentiviral vectors are capable of transducing non-dividing cells. The application of specific targeting with retroviral vectors has been problematic and the few studies of retroviral vector targeting in living animals are not efficient (Martin et al., Mol. Ther. 5, 269-274 (2002); Jiang and Dombourg, Gene Ther. 6, 1982-1987 (1999)). Inserting ligands, peptides or single chain antibodies into the retroviral receptor binding envelope subunit has been the most common approach used to alter and/or restrict the host range of retroviral vectors (Han et al., Proc Natl Acad Sci U.S.A. 92, 7947-7951 (1995); Jiang et al., J. Virol. 72, 10148-10156 (1998); Martin et al., J. Virol. 70, 2957-2962 (1996); Martin et al., J. Virol. 73, 6923-6929 (1999); Nilson et al., Gene Ther. 3, 280-286 (1996); Somia et al., Proc Natl Acad Sci U.S.A. 92, 7570-7574 (1995); Valsesia-Wittmann et al., J. Virol 68, 4609-4619 (1994)). Another approach is bridging virus vector and cells by antibodies or ligands (Boerger et al., Proc Natl Acad Sci U.S.A. 96, 9867-9872 (1999); Roux et al., Proc Natl Acad Sci U.S.A. 86, 9079-9083 (1989)). In general, most strategies have suffered from inconsistent specificity and low viral titers as a result of modification of the retroviral envelope (Han et al., Proc Natl Acad Sci U.S.A. 92, 9747-9751 (1995); Marin et al., J. Virol. 70, 2957-2962 (1995); Nilson et al., Gene Ther. 3, 280-286 (1996); Somia et al., Proc Natl Acad Sci U.S.A. 92, 7570-7574 (1995); Valsesia-Wittmann et al., J. Virol 68, 4609-4619 (1994)); Kasahara et al., Science 266, 1373-1376 (1994)). The modified envelope proteins appear to have specific binding activity but low fusion activity resulting in inefficient entry into cells (Martin et al., J. Virol. 73, 6923-6929 (1999); Zhao et al., Proc Natl Acad Sci U.S.A. 96, 4005-4010 (1999)). In the absence of specific targeting, current strategies depend upon direct injection to a localized site (Akpovare and Hersh, Curr. Opin. Mol. Ther. 1, 443-453 (1999)) or, as in the case of the only successful treatment of a heritable disease, X-linked SCID, ex vivo isolation, purification and transduction of target hematopoietic cells (Kohn et al., Nat. Med. 1, 1017-1023 (1995); Cavazzana-Calvo et al., Science 288, 669-672 (2000)).

Sindbis virus is a member of the Alphavirus genus (Schlesinger and Schlesinger, Fundamental Virology 523-539, Raven, Philadelphia (1996)). In mature Sindbis virions the plus-stranded RNA viral genome is complexed with the capsid protein to form an icosahedral nucleocapsid surrounded by a lipid bilayer embedded with two integral membrane glycoproteins, E1 and E2, that form a heterodimer and function as a unit. E1 and E2 are anchored in the membrane independently. E2 binds to the host cell receptor. E1 can mediate membrane fusion as long as it is exposed to the low pH of the endosome and in the absence of a specific interaction with a receptor. Monoclonal antibodies capable of neutralizing virus infection are usually E2 specific, and mutation of E2 is frequently associated with altered host range and virulence. E2 can be modified substantially yet retain viral infectivity. This property of E2 has been exploited to develop Sindbis virus vectors that target specific cells (Ohno et al., Nat. Biotechnol. 15, 763-767 (1997)). However, since Sindbis virus vectors are cytopathic (Tseng et al. Systemic tumor targeting and killing by Sindbis viral vectors, Nat. Biotechnol. (2003)) and unable to stably transduce the tumor cells, they cannot be used where stable expression is desired.

We previously found that the Sindbis virus envelope (with E1 and E2) is able to pseudotype oncometavirus and lentivirus vectors (Morizono et al., J. Virol., September; 75(17): 8015-20. 75, 8016-8020 (2001)). We used the flexibility of the Sindbis virus E2 protein to our advantage in developing oncometroviral and lentiviral vectors with the capacity to target specific cells. We previously reported an oncometroviral and lentiviral gene targeting system based on antibody-mediated specific binding of a modified Sindbis virus envelope (ZZ SINDBISS) that encoded the ZZ domain of protein A. We demonstrated that monoclonal antibodies directed to cell surface antigens can be used to redirect the target specificity of these vectors when pseudotyped with the modified Sindbis envelope. Of particular note, the vectors maintained high viral titers, which could be further increased by simple ultracentrifugation.

Sindbis virus has a broad natural host range. The high-affinity laminin receptor (Wang et al., J. Virol. 66, 4992-5001 (1992)) and heparin sulfate are among the known receptors (Klimstra et al., J. Virol. 72, 7357-7366 (1998)). Their
wide distribution and highly conserved nature may be in part responsible for the residual non-specific tropism observed with the ZZ SINDbis pseudotyped vector. Accordingly, there exists a need for targeted retroviral vectors with decreased binding of endogenous receptors. The present invention fulfills this and other needs.

BRIEF SUMMARY OF THE INVENTION

In order to further reduce the natural tropism of the Sindbis virus envelope and thereby increase the specificity of targeted gene transduction in vivo, we screened a panel of E2 mutants. We identified several mutants within E2 that reduced the endogenous tropism of E2. We utilized our modified ZZ SINDbis envelope, designated m168, and a lentiviral reporter vector to target P-glycoprotein (P-gp) expressing melanoma cells in the lungs of a murine model for metastatic melanoma. We demonstrate specific targeting of metastatic tumor cells through direct injection of the vector into the bloodstream.

The present invention therefore provides targeted lentiviral vectors that are pseudotyped with mutated Sindbis envelopes. In particular, mutations in the E2 protein and are used to alter viral titer, specificity, specificity index, tropism, and susceptibility to host immune response. The pseudotyped, targeted lentiviral vectors of the invention are used to transduce heterologous genes into a cell and can be used for in vivo and ex vivo therapeutic applications, as well as for diagnostic and research tool applications.

Accordingly, in a first aspect, the invention provides a pseudotyped, targeted retroviral vector comprising:

a) a mutated Sindbis envelope comprising Sindbis envelope proteins E1, E2, and E3, wherein at least one of E1, E2, or E3 is mutated as compared to a wild-type sequence;

b) a targeting moiety linked to the Sindbis envelope.

In certain embodiments, the vector further comprises a retroviral-based nucleic acid genome. In certain embodiments, the retroviral-based nucleic acid genome is a lentivirus or an oncoretrovirus genome. The genome can also optionally comprise a heterologous gene.

In certain embodiments, the vector is isolated. Typically, one or more of the E1, E2, or E3 proteins can be mutated at one or more amino acid positions. In one preferred embodiment, the vector comprises the following envelope protein mutations in comparison to wild-type Sindbis virus envelope proteins: (i) deletion of E3 amino acids 61-64; (ii) E2 K159-160AA; and (iii) E2 SLQ68-71AAA (SEQ ID NO: 3-4).

In a further embodiment, the vector additionally comprises the envelope protein mutation E1 AK226-227SG. The vectors can also have a protein binding domain that specifically binds a protein of interest (i.e., a targeting moiety, including an antibody, an integrin, a transferrin receptor). In certain embodiments, the targeting moiety is an antibody.

The invention further encompasses a packaging system comprising a cell comprising one or more nucleic acids encoding the pseudotyped, targeted retroviral vectors described herein. In a related aspect, the invention provides expression vectors comprising one or more nucleic acids encoding Sindbis envelope proteins E1, E2, and E3, wherein at least one of E1, E2 or E3 is mutated as compared to a wild-type sequence.

In another aspect, the invention provides methods of making the pseudotyped, targeted retroviral vectors of the invention, the methods comprising the steps of expressing in a cell one or more nucleic acids comprising Sindbis envelope proteins E1, E2, and E3. The vector can optionally comprise a nucleic acid comprising the retroviral based nucleic acid genome. The Sindbis envelope proteins E1, E2 and E3 and the retroviral-based nucleic acid genome can be encoded on the same or separate nucleic acids.

In a related aspect, the invention also provides methods of transducing cells with a heterologous gene; methods of treating or preventing a disease state; and methods of diagnosing a disease state, the methods comprising the step of contacting the cell with the pseudotyped, targeted retroviral vectors described herein. In certain embodiments the cells are contacted in vitro, ex vivo, or in vivo. The pseudotyped, targeted retroviral vectors are typically administered intravenously.

In another aspect, the invention provides a method for delivering a pseudotyped, targeted retroviral vector across the blood brain barrier in a subject, the method comprising the step of contacting a cell with a pseudotyped, targeted retroviral vector of the present invention, wherein the targeting moiety specifically binds to a transferrin receptor.

DEFINITIONS

“Sindbis envelope,” “ZZSINDbis,” and “m168” refer to a viral envelope comprising the Sindbis E1, E2, and E3 proteins. The terms “Sindbis E1 protein,” “Sindbis E2 protein” and “Sindbis E3 protein” or a nucleic acid encoding “Sindbis E1 protein,” “Sindbis E2 protein” and “Sindbis E3 protein” refer to nucleic acids and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleic acids, up to the full length sequence, to the nucleotide sequence of E1, E2, and/or E3; (2) bind to antibodies, e.g., polyclonal or monoclonal antibodies, raised against an immunogen comprising an amino acid sequence of an E1, E2, and/or E3 protein, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to an anti-sense strand corresponding to a nucleic acid sequence of E1, E2, and/or E3 and conservatively modified variants thereof; (4) encode a protein having an amino acid sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to a E1, E2, and/or E3 protein. The nucleic acids and proteins of the invention include both naturally occurring or recombinant molecules, as well as point mutations, including randomly generated point mutations and those generated by site-directed mutagenesis. E1, E2, and E3 are encoded by a polypeptide, the amino acid sequence of which is provided, e.g., by Accession No. VHWB, VHWVB2, and P03316; the nucleic acid sequence is provided, e.g., by Accession No. SVU09536 and V01403 (see also Rice & Strauss, Proc. Nat’l Acad. Sci. USA 78:2062-2066 (1981); and Strauss et al., Virology 133:92-110 (1984)). Other togaviridae family envelopes, e.g., from the alphavirus genus, e.g., Semliki Forest Virus, Ross River Virus, and equine encephalitis virus, can also be used to pseudotype the...
vectors of the invention. The envelope protein sequences for such Alphaviruses are known in the art.

[0021] “Pseudotype” refers to a virus particle, where the envelope or capsid includes heterologous viral proteins.

[0022] “Nucleic acid genome” refers to the genomic or nucleic acid component of a virus particle, which encodes the genome of the virus particle, including any proteins required for replication and/or integration of the genome, if required, and optionally a heterologous protein operably linked to a promoter, the promoter being either native to the protein or heterologous (viral or non-viral). The nucleic acid genome can be based on any virus, and have an RNA or DNA genome, either single stranded or double stranded. Preferably, the nucleic acid genome is from the family Retroviridae.

[0023] “Lentiviral vector” refers to viruses comprising nucleic acid genomes based on viruses of the Lentiviral genus of the family Retroviridae. Optionally, the vector encodes a heterologous gene.

[0024] “Retroviral vectors,” as used herein, refer to viruses based on viruses of the Retroviridae family. In their wild-type form, retroviral vectors typically contain a genomic nucleic acid. The pseudotyped, targeted retroviral vectors of the invention can optionally comprise a nucleic acid genome. The vectors of the invention can also comprise a heterologous gene.

[0025] “Targeting moiety” refers to a heterologous protein linked, either covalently or non-covalently, to a pseudotyped virus particle, typically linked to an envelope protein, e.g., E1, E2, or E3. The targeting moiety binds to a protein on the cell surface of a selected cell type. Representative targeting moieties include antibodies and receptor ligands.

[0026] A viral “envelope” protein, or “Env” protein, as used herein, refers to any polypeptide sequence that resides on the surface lipid bilayer of a retroviral virion whose function is to mediate the adsorption to and the penetration of host cells susceptible to infection. A retroviral envelope is formed by a cell-derived lipid bilayer into which proteins encoded by the env region of the viral genome are inserted. Envelope proteins are typically glycoproteins and usually comprise a transmembrane (TM) and a surface (SU) component linked together by disulfide bonds. Virus structure is described in detail in, for example, Coffin, et al., Retroviruses, 1997, Cold Spring Harbor Laboratory Press.

[0027] A viral “capsid,” as used herein, refers to the principal structural protein of the virion core derived from the central region of the Gag polyprotein. The capsid protein in a mature virion particle forms a shell surrounding the ribonucleoprotein complex that contains the genomic nucleic acid. This shell, which includes additional proteins, is also referred to as a capsid. A capsid shell can exist as a component of a virion without surrounding a genomic nucleic acid.

[0028] A “virion” refers to a retrovirus body, including the outer lipid bilayer which surrounds a capsid shell which in turn surrounds a genomic nucleic acid, when present. A virion of the invention, can, but need not, have a genomic nucleic acid.

[0029] “Mutated Sindbis envelope” refers to a point mutation, insertion, or deletion in the amino acid sequence of a wild-type Sindbis E1, E2, or E3 protein. The E1, E2, or E3 protein can have one or more mutations. In addition, combinations of mutations in E1, E2, and E3 are encompassed by the invention, e.g., mutations in E1 and E2, or in E2 and E3, or E3 and E1, or E1, E2, and E3. Exemplary wild type sequences of E1, E2, and E3 proteins from Sindbis strains include Accession No. VHWVB, VHWVB2, and P03316.

[0030] “Biological sample” includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood and blood fractions or products (e.g., serum, plasma, platelets, red blood cells, and the like), sputum, tissue, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; bird; reptile; or fish.

[0031] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

[0032] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[0033] A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignement of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual
A preferred example of an algorithm that is suitable for determining percent sequence identity and sequence similarity
are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402
(1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with
the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention.
Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Informa
tion (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying
short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T
when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood words act as seeds for initiating searches to find longer
HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative
alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M
(reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For
amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each
direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value;
the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments;
or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and
speed of the alignment. The BLASTN program (for nucleotide sequences) uses as a default a word length of 11, an
expectation (E) of 10, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program
uses as a default a word length of 3, and an expectation (E) of 10, and the BLAST/MS62 scoring matrix (see Henikoff &
Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a compar-
ison of both strands.

“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term encompasses nucleic acids containing known nucleotide ana-
logs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring,
which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the
reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates,
aryl phosphonates, aryl-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified
variations thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substi-
tuted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5801 (1991), Ohitsuka et
used interchangeably with gene, cDNA, mRNA, oligonucleo-
tide, and polynucleotide.

A particular nucleic acid sequence also implicitly encompasses “splice variants.” Similarly, a particular protein encoded
by a nucleic acid implicitly encompasses any protein encoded by a splice variant of that nucleic acid. “Splice vari-
ants,” as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid tran-
script may be spliced. The splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombination forms of the splice products, are included in this definition. An example of potassium channel splice variants is discussed in Leicher et al., J. Biol.

The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino
acid residues. The terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical
mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and
non-naturally occurring amino acid polymer.
tide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGC, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.

[0042] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

[0043] The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

[0044] A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochromatographic, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

[0045] The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

[0046] The term “homologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a homologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

[0047] The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42°C, or, 5×SSC, 1% SDS, incubating at 65°C, with wash in 0.2×SSC; and 0.1% SDS at 65°C.

[0048] Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1×SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

[0049] For PCR, a temperature of about 35°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C-95°C, for 30 sec-2 min., an annealing phase lasting 30 sec-2 min., and an extension phase of about 72°C for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

[0050] “Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu,
alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody will be most critical in specificity and affinity of binding.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (\(V_L\)) and variable heavy chain (\(V_H\)) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various proteases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce \(F(ab')_2\), a dimer of Fab which itself is a light chain joined to \(V_{\gamma}C_{\delta}\) by a disulfide bond. The \(F(ab')_2\) may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the \(F(ab')_2\) dimer into an Fab’ monomer. The Fab’ monomer is essentially Fab with part of the hinge region (see *Fundamental Immunology* (Paul ed., 3d ed. 1993)). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., *Nature* 348:552-554 (1990)).

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler & Milstein, *Nature* 256:495-497 (1975); Kozbor et al., *Immunology Today* 4: 72 (1983); Cole et al., pp. 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985); Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies, A Laboratory Manual* (1988); and Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986)). The genes encoding the heavy and light chains of an antibody of interest can be cloned from a cell, e.g., the genes encoding a monoclonal antibody can be cloned from a hybridoma and used to produce a recombinant monoclonal antibody. Gene libraries encoding heavy and light chains of a monoclonal antibody can also be made from hybridomas or plasma cells. Random combinations of the heavy and light chain gene products generate a large pool of antibodies with different antigenic specificity (see, e.g., Kuby, *Immunology* (3d ed. 1997)). Techniques for the production of single chain antibodies or recombinant antibodies (U.S. Pat. No. 4,946,778, U.S. Patent No. 4,816,567) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized or human antibodies (see, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks et al., *BioTechnology* 10:779-783 (1992); Lonberg et al., *Nature* 368:856-859 (1994); Morrison, *Nature* 368:812-13 (1994); Fishwild et al., *Nature Biotechnology* 14:845-51 (1996); Neuenger, *Nature Biotechnology* 14:826 (1996); and Lonberg & Huszar, *Intern. Rev. Immunol.* 13:65-93 (1995)). Alternatively, phage display technology can be used to identify antibodies and hetero-meric Fab fragments that specifically bind to selected antigens (see, e.g., McCanlery et al., *Nature* 348:552-554 (1990); Marks et al., *Biotechnology* 10:779-783 (1992)). Antibodies can also be made bispecific, i.e., able to recognize two different antigens (see, e.g., WO 93/08829; Traunecker et al., *EMBO J.* 10:3655-3659 (1991); and Suresh et al., *Methods in Enzymology* 121:210 (1986)). Antibodies can also be hetero-conjugates, e.g., two covalently joined antibodies, or immunotoxins (see, e.g., U.S. Pat. No. 4,676,980, WO 91/00360; WO 92/00373, and EP 03089).

Methods for humanizing or primatizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers (see, e.g., Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-327 (1988); Verhoeven et al., *Science* 239:1534-1536 (1988) and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

A “chimeric antibody” is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

In one embodiment, the antibody is conjugated to an “effector moiety.” The effector moiety can be any moiety of molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the antibody modulates the activity of the protein.

The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologicals. Thus, under designated immunosassay conditions, the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunosassay formats may be used to select antibodies specifically immunore-
active with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, *Antibodies: A Laboratory Manual* (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).

[0058] By “therapeutically effective dose” herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, *Pharmaceutical Dosage Forms* (vols. 1-3, 1992); Lloyd, *The Art, Science and Technology of Pharmaceutical Compounding* (1999); and Pickar, *Dosage Calculations* (1999)).

**BRIEF DESCRIPTION OF THE DRAWINGS**

[0059] FIG. 1. Schematic representation of FUHlcucW, FUIntronRW and CCRMDrSc1. FUHlcucW and FUIntronRW have the CMV enhancer and CCRMDrSc1 has the RSV enhancer/promoter substituted for the U3 region of the 5′ LTR. AU3 denotes a deletion in the U3 region of the 5′ LTR that renders the 5′ LTR of the integrated provirus transcriptionally inactive. FUHlcucW and FUIntronRW have the Ubiquitin-C promoter as an internal promoter to express humanized Firefly luciferase or humanized Renilla luciferase respectively. CCRMDrSc1 has the CMV promoter as an internal promoter to express MDRSc1 (P-glycoprotein). All vectors have the central polypurine tract (cPT). FUHlcucW and FUIntronRW contain the Woodchuck hepatitis virus post transcriptional element (WRE). CCRMDrSc1 has the human hepatitis virus post-transcriptional element (PRE). FUIntronRW has a chimeric intron derived from phiRL-CMV.

[0060] FIG. 2. HIV vector pseudotyped by ZZ SINDBIS has non-specific infectivity in the absence of specific protein in vitro and in vivo. a) 293T cells (2x10^5) were infected with TRIP GFP (ZZ SINDBIS) (34 ng of HIV p24) with or without anti-HLA (1 µg/ml). For comparison of titers, cells were infected with TRIP GFP (VSV-G) (8 ng of HIV p24). Three days after infection, EGFP expression was analyzed by flow cytometry. The titers of TRIP GFP (ZZ SINDBIS) and TRIP GFP (VSV-G) with 1 µg/ml of anti-HLA were 3x10^4 and 1x3x10^5 EGFP transduction units/100 ng HIV p24. (b) FUHlcucW (VSV-G) (15 µg HIV p24), FUHlcucW (Sindbis) (30 µg HIV p24) and FUHlcucW (ZZ SINDBIS) (30 µg HIV p24) were injected intravenously through the tail vein. Five days after injection, mice were anesthetized and injected intraperitoneally with 30 µg of D-luciferin. The reporter gene (Firefly luciferase) expression was imaged using a CCD camera for 1 min prior to imaging. The acquisition time was determined to avoid saturation of the signal.

[0061] FIG. 3. Anti-SINDBIS virus antibody blocked non-specific background infectivity of the ZZ SINDBIS pseudotyped lentiviral vector. TRIP GFP (VSV-G) (3 ng HIV p24), TRIP GFP (Sindbis) (35 ng HIV p24) and TRIP GFP (ZZ SINDBIS 103 ng HIV p24) were incubated with anti-SINDBIS virus antibody (0.1% volume) or control antibody for 1 hour at 4°C. The viruses were used for infection of 293T cells (2x10^5).


[0063] FIG. 5. Analysis of the m168 mutant by flow cytometry and Western blotting. (a) 293T cells (1x10^5) were infected with 200 µl of unconcentrated TRIP GFP (ZZ SINDBIS) (24 ng HIV p24) or TRIP GFP (m168) (40 ng HIV p24) with or without anti-HLA (1 µg/ml). Three days after infection, EGFP expression was analyzed by flow cytometry. (b) SDS-PAGE and Western blotting of ZZ SINDBIS and m168 pseudotyped virions. Ultracentrifuged samples of HIV vectors (FUHlcucW) pseudotyped by ZZ SINDBIS or m168 were lysed and subjected to SDS-polyacrylamide gel electrophoresis and Western blotting as described in the Methods section. The amount of virus for each sample was normalized by the amount of HIV p24 antigen (5 ng/sample). Viral proteins were detected with anti-Sindbis virus mouse immune ascites fluid. The band at approximately 65 kD in the ZZ SINDBIS lane is the chimeric E2 protein. The band at approximately 75 kD in the m168 lane is chimeric E2 protein with uncleaved E3 protein.

[0064] FIG. 6. The m168 pseudotyped lentiviral vector has reduced non-specific infectivity in vivo. FUHlcucW (ZZ SINDBIS) (30 µg HIV p24) and FUHlcucW (m168) were each injected into 3 mice via the tail vein. Five days after injection, mice were anesthetized and injected intraperitoneally with D-luciferin (30 µg). The reporter gene (Firefly luciferase) expression was imaged in the dorsal and abdominal aspects of the mice using a CCD camera for 1 min. The acquisition time was determined to avoid saturation of the signal.

[0065] FIG. 7. The m168 pseudotyped lentiviral vector mediates antibody-directed targeted gene transcription after systemic injection into mice. Renilla luciferase expressing B16F10MDR5 (2x10^5 cells in 150 µl of PBS) were injected into mice via the tail vein. Thirty minutes later, FUHlcucW (ZZ SINDBIS) or FUHlcucW (m168) to which we had added anti-P-glycoprotein monoclonal antibody or isotype (IgG2a) control antibody (10 µg/ml) was injected into the tail vein. The amount of each virus used for injection was normalized to the amount of HIV p24 (36 µg of HIV p24 in 150 µl PBS). Ten days later, the level of metastasis in the lungs of mice that had received B16F10MDR5 was investigated by CCD imaging to determine the level of Renilla luciferase expression described in the Methods section. Twelve days after cell and virus injection, virus infection was determined by imaging the expression level of Firefly luciferase reporter gene as described in the Methods section.

[0066] FIG. 8. Nucleic acid sequence encoding ZZ SINDBIS.

[0067] FIG. 9. Nucleic acid sequence encoding m168.

[0068] FIG. 10. Immunohistochemical analysis of metastasized tumors targeted by FUGW (m168) with anti-P-Glycoprotein. Frozen sections were prepared from the lungs of mice injected with B16F10 MDR5 cells and FUGW (m168) plus anti-P-Glycoprotein. Serial 10 µm sections were prepared and processed. a) Slides were stained for hematoxylin eosin (HE). b) An adjacent serial section (to that shown in (a)) was stained for transgene expression (EGFP) and nuclei (DAPI). c) Another adjacent serial section was stained for melanoma antigen (S-100) and nuclei (DAPI). d) A EGFP and S-100 positive colony stained with HE is pictured at a higher magnification to show the morphology of the colony.

[0069] FIG. 11. Confocal microscopy analysis of frozen liver sections prepared from mice which had been injected with B16F10 MDR5 cells, and FUGW (VSV-G) or FUGW (m168) and anti-P-Glycoprotein. The sections were stained for Kupffer cell marker F4/80 (red) and EGFP (green).

[0070] FIG. 12. a) Flow cytometric analysis of Mac-1 expression on splenocytes on splenocytes of NOD/SCID mice. b) Flow cytometric analysis of EGFP expression in splenocytes isolated from mice injected with B16F10MDR5 cells, and FUGW
(VSV-G) or FUGW (m168) and anti-P-Glycoprotein. The cells were stained to determine Mac-1 expression. EGFP expression in Mac-1 positive and negative population was analyzed.

**[0071]** FIG. 13. (a) B16/F10MDR5 cells were injected into mice via the tail vein. Twelve days later, FUhLucW (m168), to which we had added anti-P-glycoprotein monoclonal antibody or isotype control antibody, or FUhLucW (VSV-G) was injected into the tail vein. The amount of each virus used for infection was normalized to the amount of HIV p24 (2.5 µg of HIV p24 in 250 µL PBS). Fifteen days after virus injection, virus infection was determined by imaging the level of Firefly luciferase reporter gene expression. (b) The mice were sacrificed immediately after whole body imaging and each organ was isolated to image luciferase expression.

**[0072]** FIG. 14. Prostate cells can be targeted in vitro through the prostate stem cell antigen. LPSCA4 cells were derived from LNCAP cells after stable transfection of the prostate stem cell antigen (PSCA). 1x10⁵ LNCAP and LPSCA4 cells were infected with FUGW pseudotyped with m168 envelope (12 ng HIV-1 p24) without Ab targeting, or with αHLA or 1G8 mAb (1G8 mAb recognizes PSCA). Saffran et al., Proc Natl Acad Sci (2001) 98:2658-2663). Three days after infection, eGFP expression was analyzed by flow cytometry (ten thousand events acquired per sample). The x-axis indicates eGFP fluorescence intensity. Percentage and mean fluorescence intensity of the positive population (R2) is indicated in each plot. Infection of LPSCA4 cells targeted with 1G8 is comparable to infection targeted with αHLA, whereas in LNCAP cells targeting with 1G8 antibody gives background levels similar to those without any antibody targeting.

**[0073]** FIG. 15. Transcription from the PSE-BC promoter in vitro in prostate cell lines (A) and non-prostate cell lines (B). 1x10⁵ cells were infected with lentivirus vectors expressing eGFP under the control of the ubiquitin-C promoter (FUGW) or the PSE-BC promoter (FPGW) pseudotyped with VSV-G (40 ng of HIV-1 p24). Three days after infection eGFP expression was analyzed by flow cytometry (ten thousand events acquired per sample). The x-axis indicates eGFP fluorescence intensity. Percentage and mean fluorescence intensity of the positive population (R2) is indicated in each plot. Expression from the PSE-BC promoter is comparable to ubiquitin-C promoter in prostate cell lines and up to 50 times lower in non-prostate cell lines.

**[0074]** FIG. 16. New targeting envelope (2,2), comprised of m168+E1 AK226-227SG, mediated transferrin receptor (TIR) targeted gene transduction more efficiently than previous targeting envelope (m168). 4x10⁶ HUVEC cells were infected with lentiviral vector (40 ng HIV-1 p24) pseudotyped with m168 envelope protein or 2.2 envelope protein with or without anti-transferrin receptor antibody (2 µg/ml). The lentiviral vector carried EGFP as reporter gene. Three days after infection, EGFP expression was analyzed by flow cytometry. The x-axis indicates EGFP fluorescence intensity. Percentage of the positive population is indicated in each plot.

**[0075]** FIG. 17. Targeting envelope mediates targeted gene transduction to CNS via transferrin receptor (TIR). Lentiviral vector (3 µg HIV-1 p24) pseudotyped with 2.2 envelope protein was injected into NOD/SCID mice via the tail vein with or without anti-transferrin receptor antibody (50 µg/ml). The lentiviral vector carried Firefly luciferase as reporter gene. Five days after injection, mice were anesthetized and injected intraperitoneally with D-luciferin (30 mg). The reporter gene expression was imaged using a CCCD camera. Luciferase expression from the brain and spinal column was confirmed by removing the skin from the back after sacrifice.

**DETAILED DESCRIPTION**

**[0076]** Targeted gene transduction to specific tissues and organs via intravenous injection would be the ultimate preferred method of gene delivery. Here, we report successful targeting in a living animal via intravenous injection of a lentiviral vector pseudotyped with a modified chimeric Sindbis virus envelope. After intravenous administration into mice, the previously reported parental vector has non-specific infectivity in liver and spleen due to the residual natural tropism of Sindbis virus. Mutagenesis of domains within the Sindbis envelope ablated regions necessary for this natural tropism. M168 pseudotypes had significantly less non-specific infectivity to liver and spleen and these pseudotypes have high titers and high targeting specificity. A murine cancer model for metastatic melanoma was utilized to test specific targeting with m168. Human P-glycoprotein was ectopically expressed on the surface of melanoma cells and targeted by the m168 pseudotyped lentiviral vector conjugated with anti-P-glycoprotein antibody. M168 pseudotypes successfully targeted metastatic melanoma cells growing in the lung after systemic administration via tail vein injection. This targeting technology has applications not only for cancers but also for genetic, infectious and autoimmune diseases.

**[0077]** The present invention therefore provides a pseudotyped virus or viral vector comprising an envelope comprising Sindbis E1, E2, and E3 proteins linked to a targeting moiety. The vector optionally further comprises a viral nucleic acid from the Retroviridae family, preferably the lentiviral genus. The vector can also optionally comprise a heterologous gene.

**[0078]** Structurally, at least one of the E1, E2, or E3 proteins has one or more mutations (preferably point mutations) in comparison to a wild type Sindbis or the Sindbis ZZ envelope sequence (SEQ ID NO:2; m1 (deletion of E3 amino acids 61-64), m2 (E2 R1D), m3 (m1+m2), m4 (deletion of E2 amino acids 68-71), m5 E2 S114 P), m6 (E2 KE159-160AA), m7 (E2 E216A T218A), m8 (E2 SLKQ68-71AAAA), m9 (E3 RSKRS60-64AAAAA), m16 (m1+m6), m17 (m1+m7), m18 (m1+m8) or E1 AK226-227SG. In one embodiment, the mutation is exemplified by the m168 sequence (SEQ ID NO:4), which comprises the mutations m1 (deletion of E3 amino acids 61-64), m6 (E2 KE159-160AA), and m8 (E2 SLKQ68-71AAAA). In another embodiment, the m168 sequence comprises a further mutation in the E1 domain that makes the m168 titer 2-10 fold higher. The sequence “agectctcecgag” on the sequence of m168 was modified to “agectctcctcegg” (SEQ ID NOs: 5 and 6). In this embodiment, the m168 sequence is further modified to eliminate cholesterol dependence for cell entry, (e.g. E1 AK226-227SG).
Mutations into one or more of the Sindbis viral envelope protein sequences can be introduced using any known methods in the art. Mutations can be targeted or random. For example, targeted mutations can be introduced using site-directed mutagenesis, for instance employing overlapping PCR or overlap extension PCR (see, for example, Aiyar, et al., Methods Mol Biol (1996) 57:177-91; and Pogulis, et al., Methods Mol Biol (1996) 57:167-76). Alternatively, mutations can be introduced by taking advantage of the error prone replication process of Sindbis viruses, which lack proof-reading and mismatch repair activities, and recombination between quasispecies in a virus population, for instance, by using a replication competent virus (see, Domingo and Holland, Annu Rev Microbiol (1997) 51:151-178). Mutant Sindbis virus envelope proteins of particular interest have a diminished ability to bind to endogenous receptors and therefore demonstrate decreased background infectivity in comparison to wild-type sequences. Preferably, the mutated Sindbis virus envelope proteins of the present invention have a decreased ability to bind to glycosaminoglycans (GAGs), including heparin sulfate (HIS), in comparison to wild-type sequences.

The targeting moiety is covalently or non-covalently linked to the E1, E2, or E3 protein, preferably the E2 or E3 protein, or is linked to another portion of the envelope. In one embodiment, the targeting moiety is linked to E1, E2, or E3 via non-covalent interactions with a protein binding domain, where the protein binding domain is fused with E1, E2, or E3. In one embodiment, the protein binding domain is fused with E2 or E3. Exemplary protein binding domains include, e.g., the ZZ domain of protein A, streptavidin, avidin, a leucine zipper, a STAT protein N terminal domain, an FK506 binding protein, integrin binding sequence “4C-RGD” (CDRCGDCCFC encoded by tegaagtagagagga-gtggctcggtc), and transferrin receptor targeting sequence “B6” (GHKAKGPRK encoded by ggctgatgagagga-gtggctcggtc) (see, e.g., O’Shea, Science 254: 539 (1991); Baralund-Pour et al., Curr Top Microbiol Immunol 211:121-128 (1996); Klemm et al., Annu. Rev. Immunol. 16:590-599 (1998); Klemm et al., Annu. Rev. Immunol. 16:590-592 (1998); Ho et al., Nature 382:822-826 (1996); Pomerantz et al., Biochem. 37:965 (1998); and Xia et al., Virology (2000) 74:11359-66). In another embodiment, the targeting moiety is a fusion protein with either the E1, E2, or E3 protein. In one embodiment, the targeting moiety is fused with the E2 or the E3 protein. The targeting moiety can be, e.g., an antibody, such as a monoclonal or single chain antibody that specifically binds to an antigen or a cell surface molecule, or a ligand or binding partner of a cell surface molecule.

The targeting moiety can target normal or diseased tissue. For example, the targeting antigen can be directed to a transferrin receptor for delivery of the present vectors across the blood-brain barrier. The targeting moiety also can be directed to marker proteins indicative of diseases including cancers (e.g., breast, lung, ovarian, prostate, colon, lymphoma, leukemia, and melanoma); autoimmune disease (e.g., myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and diabetes mellitus); infectious disease, including infection by HIV, HCV, HBV, CMV, and HPV; and genetic diseases including sickle cell anemia, cystic fibrosis, Tay-Sachs, β-thalassemia, neurofibromatosis, polycystic kidney disease, hemophilia, etc. In certain embodiments, the targeting moiety targets a cell surface antigen specific to a particular cell or tissue type, e.g., lymphocytes, myocytes, keratinocytes, neurons, hepatocytes, lung, kidney, muscle, vascular, thyroid, ocular, breast, ovarian, testis, prostate tissue.

Exemplary antigens and cell surface molecules for targeting include, e.g., P-glycoprotein, Her2/Neu, erythropoietin (EPO), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGF-R), cadherin, carcinomaembryonic antigen (CEA), CD4, CD8, CD19, CD20, CD33, CD34, CD45, CD117 (c-kit), CD133, HLA-A, HLA-B, HLA-C, chemokine receptor 5 (CCR5), stem cell marker ABCG2 transporter, ovarian cancer antigen CA125, immunoglobulins, integrins, prostate specific antigen (PSA), prostate stem cell antigen (PSCA), dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DCSIGN), thyroglobulin, granulocyte-macrophage colony stimulating factor (GM-CSF), myogenic differentiation promoting factor-1 (MyoD-1), Leu-7 (CD57), Leu-M1, cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 (Ki-67), viral envelope proteins, HIV gp120, transferrin receptor, etc. Any cell surface protein, known in the art or yet to be identified, preferably expressed on a particular cell or tissue type can find use as a potential target for the pseudotyped, targeted vector of the invention.

The pseudotyped, targeted vectors of the invention can optionally comprise a genomic nucleic acid. The nucleic acid genome can be from any suitable virus and in one embodiment, is derived from the Retroviridae family of viruses, e.g., from the lentiviral genus: HIV1, HIV2, SIV, FIV, BIV, Visna, CAEV, and ELAV; and from oncogenic retroviruses or oncoviruses, e.g., avian sarcoma/leukosis viruses (ASLV); mamalian C-type viruses (murine leukemia viruses (MuLV); feline leukemia viruses (FeLV)); B-type viruses (mouse mammary tumor viruses (MMTV); D-type viruses; and HTLV-BLV group of viruses (human T cell leukemia viruses (HTLV)). Preferably, the oncogenic retroviruses lack an oncogene. Retroviruses are reviewed in Coffin, et al., Retroviruses, 1997, Cold Spring Harbor Laboratory Press. The nucleic acid genome is based on any suitable virus, and contains genetic components and encodes proteins so that the genome can be replicated and transcribed. However, vectors of the present invention can be replication competent or replication incompetent. In one embodiment, the nucleic acid genome is from the family Retroviridae and contains genetic components and encodes proteins so that it can be reverse transcribed and integrated into the host genome. Optionally, the genome is replication incompetent so that it cannot make productive, infectious viral particles. In certain embodiments, the genome is replication competent. Retroviral nucleic acid genomes known to those of skill in the art can be used in the invention, or made according to methods known to those of skill in the art (see, Coffin, et al, supra). Within the genome, the E1, E2, E3 and optional heterologous gene sequences can be encoded as individual polypeptides, or one or more fusion proteins. The E1, E2, E3 and optional heterologous gene sequences can be on the same or separate nucleic acid sequences. The nucleic acid genome can be RNA or DNA.

Vectors that do not comprise a genomic nucleic acid find use in the targeted delivery of a desired protein. For example, a protein to be delivered can be expressed as a fusion protein with a viral protein that is incorporated into a viral capsid. Viral proteins that are incorporated into a capsid shell, including, for example, the virion-associated regulatory proteins, viral protein r (VPR), viral protein x (VPX), and inte-

[0086] The genome also optionally comprises a heterologous gene operably linked to a promoter, either a viral promoter or a heterologous promoter. The heterologous gene can be a marker gene, a cytotoxic gene, a gene encoding an inhibitory sequence or protein for therapeutic applications, or a gene encoding a wild type protein for gene therapy applications. Exemplary marker genes include luciferase, a fluorescent protein (green fluorescent protein, red fluorescent protein, yellow fluorescent protein), and β-galactosidase.


[0088] Packaging cells and systems, packaging techniques and vectors for packaging the nucleic acid genome into the pseudotyped viral particle are also known to those of skill in the art and can be made according to methods known to those of skill in the art (see, for example, Polo, et al, *Proc Natl Acad Sci USA*, (1999) 96:4598-4603). Methods of packaging include using packaging cells that permanently express the envelope components, or by transiently transfecting cells with plasmids encoding the components of the vector, or by using an adenoviral system that encodes the components of the vector. Viral packaging cells and kits are commercially available, for example, from BD Sciences/Clontech in Mountain View, Calif.

[0089] The pseudotyped virus of the invention can be used for diagnostic and therapeutic applications, as well as for research tool applications. Diagnostic applications include both in vitro, ex vivo, and in vivo uses, e.g., in vivo imaging. Therapeutic applications include both in vivo, in vitro, and ex vivo uses. For example, a virus particle of the invention can be administered to a subject via IV injection to treat or prevent cancers, e.g., breast, lung, ovarian, prostate, colon, lymphoma, leukemia, and melanoma; autoimmune disease such as myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and diabetes mellitus; infectious disease such as infection by HIV, HCV, HVB, CMV, and HPV; and genetic diseases such as sickle cell anemia, cystic fibrosis, Tay-Sachs, β-thalassemia, neurofibromatosis, polyepithelial kidney disease, hemophilia, etc. For in vivo applications, preferably the targeting moiety is covalently linked. The virus particles of the invention can also be administered ex vivo, e.g., to whole bone marrow by targeting CD34+ cells with the targeting moiety. In this embodiment, the targeting moiety can be covalently or non-covalently linked (e.g., via protein A or its ZZ domain). The virus particles can be used for diagnostic applications with heterologous marker genes, and can be used as research tools to transduce specific cell types. The targeted Sindbis envelope of the invention can also be used to target cell to cell interactions, by expressing the targeted envelope in a cell such as a lymphocyte, and then allowing the cell to contact the targeted cell in vivo, ex vivo.
well as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., Remington’s Pharmaceutical Sciences, 17th Ed., 1989). Administration can be in any convenient manner, e.g., by injection, oral administration, inhalation, transdermal application, or rectal administration.

In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravenously or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of comsums can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by nucleic acids for ex vivo therapy can also be administered intravenously or parenterally as described above.

The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

In determining the effective amount of the vector to be administered in the treatment or prophylaxis of conditions owing to diminished or aberrant expression of the protein, the physician evaluates circulating plasma levels of the vector, vector toxicities, progression of the disease, and the production of anti-vector antibodies. In general, the dose equivalent of a naked nucleic acid from a vector is from about 1 µg to 100 µg for a typical 70 kilogram patient, and doses of vectors are calculated to yield an equivalent amount of therapeutic nucleic acid.

For administration, compounds and transduced cells of the present invention can be administered at a rate determined by the LD50 of the inhibitor, vector, or transduced cell type, and the side-effects of the inhibitor, vector or cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

Targeted Lentiviral Vectors with Mutated Sindbis Envelopes

Methods

Plasmid construction. All mutants of plntron ZZ SINDbis were generated using a site directed mutagenesis kit (Stratagene, La Jolla, Calif.). Initially, the envelope region of plntronZZ SINDbis was cloned into pB5-SKII. Mutagenesis was performed using various oligonucleotide corresponding to the mutations (Table 1) following the manufacturer’s protocol. The mutations were confirmed by sequence analysis. The sequenced regions were then cloned back into plntron ZZSINbIS. CCR MDRsc1 was constructed from prRL-cPPTCMV-X-PRE (kindly provided by Dr. William Osborne) (Barry et al., Hum. Gene Ther. 12, 1103-1108 (2001)) and ha-MDRsc (kindly provided by Dr. Brian Sorrentino) (Bunting et al., Blood 92, 2269-2279 (1998)). FU/LucW was constructed from FUGW (kindly provided by Dr. David Baltimore) and pGL3-Basic (Promega, Madison, Wis.). FUItronKW was constructed from FUGW and phRL-CMV (Promega).

<table>
<thead>
<tr>
<th>Mutant</th>
<th>Domain</th>
<th>Details of mutation</th>
<th>* Selectivity Index</th>
<th>** Titer (% of ZZ SINDbis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZZ SINDbis</td>
<td>deletion of E3 a.a. 61-64</td>
<td>9</td>
<td>4.9</td>
<td>100</td>
</tr>
<tr>
<td>m1</td>
<td>R1</td>
<td>E2 R1D</td>
<td>21</td>
<td>1.4</td>
</tr>
<tr>
<td>m2</td>
<td>R1</td>
<td>m1 + m2</td>
<td>21</td>
<td>1.4</td>
</tr>
<tr>
<td>m3</td>
<td>R1</td>
<td>E3 RSKRS60-6AAAAA</td>
<td>32</td>
<td>9.2</td>
</tr>
<tr>
<td>m4</td>
<td>R2</td>
<td>deletion of E2 a.a. 68-71</td>
<td>11</td>
<td>5.3</td>
</tr>
<tr>
<td>m5</td>
<td>R5</td>
<td>E2 SI14P</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>m6</td>
<td>R4</td>
<td>E2 K159A E160A</td>
<td>10</td>
<td>4.9</td>
</tr>
<tr>
<td>m7</td>
<td>R5</td>
<td>E2 E216A T218A</td>
<td>11</td>
<td>4.6</td>
</tr>
</tbody>
</table>

1st combination of mutations

| ZZ SINDbis | m1 | deletion of E3 a.a. 61-64 | 34 | 6.9 | 100 | 100 |
| m16 | R1 + m6 | 151 | 14.9 | 53 | 115 |
| m17 | R1 + m7 | 80 | 12.6 | 21 | 87 |
| m18 | R1 + m8 | 120 | 15.4 | 42 | 105 |
TABLE 1-continued

<table>
<thead>
<tr>
<th>Sindbis Envelope Mutations</th>
<th>* Selectivity Index*</th>
<th>** Titer (% of ZZ SINDIBIS)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutant</td>
<td>Domain</td>
<td>Details of mutation</td>
</tr>
<tr>
<td>ZZ SINDIBIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>m1</td>
<td>R1</td>
<td>deletion of E3 a.a. 61-64</td>
</tr>
<tr>
<td>m168</td>
<td>R1 + 2 + 4</td>
<td>m1 + m6 + m8</td>
</tr>
</tbody>
</table>

The results are average of three independent infection and flow cytometry. a.a. is abbreviation of amino acid.

* Selectivity index was calculated as follows: (% EGFP + cells infected in the presence of anti-HLA monoclonal antibody)/(% EGFP + infected in the absence of antibody).
** Titer was calculated as follows: (% EGFP positive cells infected by lentiviral pseudotyped by each mutant in the presence of anti-HLA monoclonal antibody)/% EGFP positive cells infected by lentiviral vector pseudotyped by ZZ SINDIBIS in the presence of anti-HLA monoclonal antibody) x 100
*** m5 did not have any infectivity.

[0100] Cells. Hep G2 cells and B16F10 cells were purchased from ATCC and cultured in DMEM (Invitrogen, Carlsbad, Calif.) containing FCS (10%) (Hyclone, Logan, Utah), penicillin (100 units/ml) and streptomycin (100 µg/ml). 293T cells were grown in IMDM (BiRC Biosciences, Lenexa, Kans.) containing FCS (10%), penicillin (100 units/ml) and streptomycin (100 µg/ml). B16F10MDR5 cells were generated by stable gene transduction of CCRM3Rsc1 (VSV-G). After lentiviral gene transduction, cells were cloned by limited dilution. The clones were analyzed for the expression of MDR-1 (P-gp) by flow cytometry. The clone designated B16F10MDR5 showed the highest level of the expression of the MDR-1 gene and was used for all further experiments.

[0101] Virus production. All lentivirus vectors were produced by calcium phosphate-mediated transient transfection of 293T cells. 293 T cells (1.8x10⁶) were transfected with pCMV8.2DVP (12.5 µg), the appropriate lentiviral vector plasmid (12.5 µg), and pHCMVG (5 µg) or plenitron SINDIBIS, plton ZZ SINDIBIS or mutants derived thereof (10 µg). For in vitro screening of the mutant plorton ZZ SINDIBIS, TRIP GFP (kindly provided by Dr. Pierre Charnaveau) (Zennou et al., Cell. 101, 173-185 (2000)) was used as the lentiviral vector plasmid. CCRM3Rsc1 was used as the lentiviral vector and pHCMVG as the envelope plasmid for generation of the MDR-1 expressing lentiviral vector. The Remilla luciferase expressing lentiviral vector was generated using FUntronRW as the lentiviral vector plasmid and pHCMVG as the envelope plasmid. FUnHucW was used as the lentivirus vector for generation of the humanized Firefly luciferase expressing lentivirus vector.

[0102] Antibodies. Anti-HLA ABC was purchased from Sigma (St. Louis, Mo.). Anti-P-gp (multiple drug resistant gene-1 product) was purchased from Kamiya Biomedical Company (Seattle, Wash.). Anti-Sindbis virus ascites fluid and control ascites fluid were purchased from ATCC. Antibody II-2 receptor beta-chain (TM-Beta 1) was kindly provided by Dr. Masayuki Miyasaka.

[0103] In vivo infection of cells. 293T cells (5x10⁴) and HepG2 cells (5x10⁴) were seeded on 24-well plates the day before infection. The cells were incubated with 200 µl of unconcentrated HIV vector (TRIP GFP) pseudotyped by ZZ SINDIBIS or its mutants with or without anti-HLA (1 µg/ml) for 2 hours at 37°C with 5% CO₂. The virus was removed and replaced with fresh medium (1 ml). Three days post infection; the cells were trypsinized and analyzed by flow cytometry. Background infectivity of TRIP GFP (ZZ SINDIBIS) was blocked by anti-Sindbis virus ascites fluid. Anti-Sindbis virus ascites fluid or control ascites fluid was added to unconcentrated TRIP GFP (VSV-G), TRIP GFP (Sindbis) or TRIP GFP (ZZ SINDIBIS) (0.1% volume) and incubated for 1 hour at 4°C. The virus was used for infection of 293T cells and infectivity was analyzed as previously described.

[0104] Immunoblot assay. The HIV vectors (FUnHucW) pseudotyped with ZZ SINDIBIS or m1 68 were concentrated 100-fold by ultracentrifugation and resuspended in PBS. The concentrated virus was mixed with equal volume of electrophoresis loading buffer [glycerol (20%), β-mercaptoethanol (10%), sodium dodecyl sulfate (4%), Tris-HCl pH 6.8 (125 mM), bromophenol blue (0.02%) and boiled for 5 min. The amount of virus sample was normalized to the amount of HIV p24 (5 pg of p24/ lane). The samples were subjected to electrophoresis through an SDS polyacrylamide gel (10%) as described previously (Morizzo et al., J. Virol., September, 75(17):8015-20. 75, 8016-8020 (2001)). Immunoblot analysis was performed with anti-Sindbis virus ascites fluid and horseradish peroxidase-conjugated anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.). The protein bands were visualized by enhanced chemiluminescence (Pierce, Rockford, Ill.).

[0105] In vivo analysis of background infection. HIV vector (FUnHucW) pseudotyped by VSV-G, Sindbis virus, ZZ SINDIBIS or m1 68 were injected into the tail vein of 6-week old female NOD/SCID mouse. The amount injected for each virus was normalized to the amount of HIV p24 (30 pg of HIV p24 in 300 µl PBS). Five days post injection, the mice were anesthetized and injected with D-luciferin (3 mg/mouse) (Xenogen, Alameda, Calif.) intraperitoneally. CCD images were obtained using a cooled IVIS CCD camera (Xenogen), and analyzed with IGOR-PRO Living Image Software. The data acquisition was performed 20 min after D-luciferin injection for 1 min. Mice were sacrificed by CO₂ asphyxiation after CCD imaging. The organs from each mouse were excised and genomic DNA was isolated using a Dneasy kit (QIAGEN, Valencia, Calif.) following the manufacturer's protocol. Quantitation of the vector copy number and cell number in the DNA isolate was performed by using SYBR green real time PCR kit (QIAGEN) and an ABI PRISM 7700 sequence detector (Perkin Elmer, Wellesley, Mass.). The primers for the analysis of vector copy number (Firefly luciferase) were Fluc-a (gatacgcccgcttgctg) and Fluc-b (gatctagcgggttcgatg). The standard for quantification of vector copy number was FUnHucW. The primers for the analysis of cell number (mouse beta actin) were beta-actin-F
(caacctcactgaagtgtgac) and beta-actin-R (caacacaggtatgcttcgct). The standard for the analysis of cell number was made using genomic DNA isolated from normal mouse peripheral blood mononuclear cell.

[0106] Targeted infection of melanoma cells in vitro. B16F10MDR5 cells (1 x 10⁶) were seeded on 48-well plate at the day before infection. The cells were incubated with FUULucW (ZZ SINDBIS) or FUULucW (m168) (10 ng HIV p24) with or without anti-P-gp antibody (1 μg/ml) for 2 hours at 37° C. with 5% CO₂. The virus was subsequently removed and replaced with fresh medium (500 μl). Three days post infection, cells were lysed in passive lysis buffer (Promega) and Firefly luciferase activity was measured following the manufacturer’s protocol.

[0107] Targeted infection of melanoma cells in vivo. To express Renilla luciferase as a marker, the human P-gp expressing mouse cell line, B16F10MDR5, was transduced by the lentiviral vector FUntronRW (VSV-G). One day prior to subsequent cell and virus injection, TMBeta-1 (1 μg) was injected into 6-week old female NOD/SCID mice. Renilla luciferase expressing B16F10MDR5 (2 x 10⁵ cells in 150 μl of PBS) were injected into mouse via the tail vein. Thirty minutes later, FUULucW (ZZ SINDBIS) or FUULucW (m168), to which we had added anti-P-glycoprotein monoclonal antibody or isotype (IgG2a) control antibody (10 μg/ml) was injected into the tail vein. The amount of each virus used for injection was normalized to the amount of HIV p24 (36 pg of HIV p24 in 150 μl PBS). Ten days after cells and virus injection, lung metastasis of B16F10MDR5 was determined by imaging the Renilla luciferase. Mice were anesthetized and coelenterazine (20 μg) (Promega, Pinetop, Ariz.) was injected via the tail vein. Data acquisition was performed directly following coelenterazine injection for 1 min. Twelve days after cell and virus injection, virus infection was determined by imaging the expression of Firefly luciferase reporter gene. Mice were anesthetized and injected intraperitoneally with D-luciferin (6 mg/mouse). Imaging was performed as previously described. Mice were sacrificed after imaging using D-Luciferin. To isolate tumor cells, whole lung was isolated, ground and passed through a cell strainer (BD, San Jose, Calif.). The cells were cultured for 10 days in DMEM supplemented with FCS (20%), penicillin (100 units/ml) and streptomycin (100μg/ml). Cultured cells were trypsinized, counted, stained by anti-P-Glycoprotein monoclonal antibody conjugated to PE (BD) and analyzed by flow cytometry. More than 99% of cells expressed P-gp demonstrating that nearly all of the cells we harvested were B16F10MDR5 cells. Cells were not recovered from control mice that did not receive tumor cells. One million cells were then harvested and lysed in passive lysis buffer (200 μl) (Promega) and analyzed for Firefly luciferase activity following the manufacturer’s protocol. Genomic DNA was isolated using a DNAeasy kit (QIAGEN). The primers and standard for quantitation of vector copy number were the same as those used to quantify the background level of infection as previously described. Quantitation of the cell number was performed using primers for marine beta-actin as described above and the standard was generated by using known numbers of B16F10MDR5 cells.

Results

[0108] We previously demonstrated specific targeting of our ZZ SINDBIS lentiviral vector and marine retroviral vectors to CD4+ and HLA+, cells using monoclonal antibodies specific for CD4 and HLA (Morizono et al., J. Virol., September 75(17):8015-20, 75, 8016-8020 (2001)). These vectors demonstrated an approximately 30-fold selectivity for infection of target cells in the presence of the specific cell surface monoclonal antibody. Our goal is to utilize these vectors for direct targeting of gene therapy vectors to specific target cells via direct injection in the bloodstream. We utilized lentiviral vectors bearing two distinct types of reporter genes to assess transduction efficiency (FIG. 1). The EGFP-expressing virus vector allowed a quantitative assessment of infectivity in vitro as monitored by flow cytometry (Zennou et al., Cell, 101, 173-185 (2000)). We utilized both Firefly and Renilla luciferase-expressing virus vectors and non-invasive cooled charged-coupled device (CCCD) imaging to quantitate the level of specific targeting of vectors in live mice (Bhumik and Gambhir, Proc Natl Acad Sci U S A 99, 377-382 (2002)).

HIV Vector Pseudotyped by ZZ Sindbis has Non-Specific Infectivity In Vivo.

[0109] FIG. 2a shows the typical enhancement in infectivity of the ZZ SINDBIS pseudotyped virus vector in vitro using a monoclonal antibody directed to HLA. We observed approximately a 30-fold enhancement of EGFP+ cells in the presence of anti-HLA antibody relative to that seen in the absence of monoclonal antibody. As a comparison, VSV-G envelope pseudotyped virus infected cells at a high level in the absence of antibody. The titer of ZZ SINDBIS virus is usually about 5-fold lower than that of VSV-G pseudotyped virus but, like VSV-G pseudotypes can be further concentrated at least 100-fold by ultracentrifugation.

[0110] ZZ SINDBIS pseudotyped virus vectors expressing Firefly luciferase were utilized to quantitate the level and specificity of targeting in transduced cells in the organs of live mice. We used a lentiviral vector containing the Ubiquitin-C promoter for in vivo experiments since this vector has been shown to express well in all mouse tissues (Lois et al., Science, 295, 868-872 (2002)). ZZ SINDBIS virus vectors were injected into the tail vein in the absence of monoclonal antibody. The expression of virus was monitored by luciferase expression utilizing CCD imaging (FIG. 2b). Lentiviral vectors pseudotyped with each of the envelopes, VSV-G, wild type Sindbis, and ZZ SINDBIS infected both liver and spleen. VSV-G and wild type Sindbis pseudotypes resulted in a strong signal. Although ZZ SINDBIS gave a weaker signal, consistent with its infectivity in vitro, there was still clear expression in liver and spleen. Injection of recombinant luciferase did not show a signal in major organs, indicating that the signal observed with ZZ SINDBIS was due to infection of cells in the organs (data not shown). We verified infection of Sindbis and ZZ SINDBIS in the liver and spleen by quantitative DNA PCR analysis (Table 2).

<table>
<thead>
<tr>
<th>Vector</th>
<th>Liver</th>
<th>Heart</th>
<th>Spleen</th>
<th>Kidney</th>
<th>Lung</th>
<th>Ovary</th>
</tr>
</thead>
<tbody>
<tr>
<td>No vector</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>SINDBIS</td>
<td>569</td>
<td>1407</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>ZZ SINDBIS</td>
<td>75</td>
<td>538</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>ZZ SINDBIS</td>
<td>397</td>
<td>520</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>ZZ SINDBIS</td>
<td>146</td>
<td>295</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>m168</td>
<td>26</td>
<td>36</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
</tbody>
</table>
### TABLE 2-continued

<table>
<thead>
<tr>
<th>Vector</th>
<th>Liver</th>
<th>Heart</th>
<th>Spleen</th>
<th>Kidney</th>
<th>Lung</th>
<th>Ovary</th>
</tr>
</thead>
<tbody>
<tr>
<td>m168</td>
<td>66</td>
<td>*&lt;</td>
<td>15</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
<tr>
<td>m168</td>
<td>38</td>
<td>*&lt;</td>
<td>28</td>
<td>*&lt;</td>
<td>*&lt;</td>
<td>*&lt;</td>
</tr>
</tbody>
</table>

Genomic DNA from each organ was isolated and analyzed as described in materials and methods.

*< represents undetectable.

The threshold for the copy number for detection from each organ was as below.

Liver: 11 copies/10^6 cells; Heart: 26 copies/10^6 cells. Spleen: 3 copies/10^6 cells. Kidney: 5.3 copies/10^6 cells, Lung: 8.3 copies/10^6 cells. Ovary: 13 copies/10^6 cells.

The Non-Specific Infectivity of ZZ Sindbis Pseudotypes is Due to Sindbis Envelope Sequences.

[0111] We further investigated the nature of the non-specific background infectivity of ZZ SINDBIS pseudotypes. A mouse polyclonal antibody which neutralizes wild type Sindbis virus infectivity was utilized to demonstrate that the background infectivity was the result of Sindbis virus domains and not the ZZ protein A sequences (FIG. 3). Using flow cytometry we determined that the level of GFP^+^ cells in the wild type and ZZ SINDBIS virus pseudotypes was substantially reduced in the presence of the anti-Sindbis antibody. Infectivity of VSV-G pseudotypes was not blocked nor was infection with the control antibody. These results indicate that Sindbis virus domains within the Sindbis envelope are responsible for the non-specific infectivity of ZZ SINDBIS pseudotypes. Thus, we undertook a structure-function analysis of the Sindbis virus envelope through site-directed mutagenesis of ZZ SINDBIS with the aim of ablating residual background infectivity.

[0112] Identification of a ZZ SINDBIS E2 mutant with enhanced cell targeting specificity. We first determined the regions responsible for the residual infectivity of our ZZ SINDBIS envelope. The domains we targeted for mutagenesis have previously been reported to affect binding to target cells, block epitopes for neutralizing antibody and function in Sindbis virus tropism (Klimstra et al., *J. Virol.* 72, 7357-7366 (1998); London et al., *Proc Natl. Acad Sci U.S.A.* 89, 207-211 (1992); Klimstra et al., *J. Virol.* 73, 6299-6306 (1999); Byrnes and Griffin, *J. Virol.* 74, 644-651 (2000); Pence et al., *Virol.* 175, 41-49 (1990); Gardner et al., *J. Virol.* 74, 11849-11857 (2000); Dubuisson and Rice, *Journal of Virology* 67, 3363-3374 (1993); Polo and Johnston, *J. Virol.* 65, 6358-6361 (1991); Lee et al., *J. Virol.* 76, 6302-6310 (2002)). All these domains were located in the E2 protein of the Sindbis virus envelope (FIG. 4). We analyzed E2 mutant pseudotyped virus vectors for infectivity in 293T cells using flow cytometry. The infectivity of mutants was tested on two different cell types, 293T, a human kidney cell line used for standard titration of virus stocks and HepG2 cells, derived from a human hepatocellular carcinoma (Table 1). We tested infectivity in HepG2 cells, because of the background infectivity we observed in liver cells in vivo. We identified several E2 mutants with reduced levels of nonspecific infectivity and thus, an enhanced selectivity for targeting. Since some of these mutations also reduced the titer of viruses produced, we combined the mutations conferring enhanced selectivity with other mutations that enhanced infectivity. Five domains of Sindbis E2 previously reported to affect the infectivity of Sindbis virus were analyzed for their level of infectivity. Mutation m1 in domain R1 enhanced the selectivity on 293T cells relative to wild type ZZ SINDBIS virus. However, this mutation also resulted in a decrease in virus titer. Mutations in domain R4 enhanced the titer without altering the specificity. Combining mutation m1 and m6 resulted in partial restoration of the titer and maintenance of the higher selectivity of m1. A double mutant of m1 and m8 resulted in enhanced selectivity on HepG2 liver cells. The combination of mutations of m1, m6, and m8 in domains R1, R2, and R4, respectively, resulted in a pseudotyped virus with enhanced selectivity on 293T and HepG2 liver cells while maintaining stability during concentration by ultracentrifugation high viral titers. This mutant ZZ SINDBIS envelope was termed m168. Our data is consistent with previous studies that demonstrate the role of the R1 and R2 domains for heparin sulfate binding and the R5 domain for rescue of the reduced titer of an R1 mutant in replication competent Sindbis virus (Heidner et al., *J. Virol.* 68, 2683-2692 (1994)). Identification of a neurotropic strain of Sindbis virus suggested use of an alternative receptor in neuronal cells (Lee et al., *J. Virol.* 76, 6302-6310 (2002)), m168 also displayed a higher level of specificity than ZZ SINDBIS (>20-fold) in the neuroblastoma cell line, NB41A3 (data not shown).

Enhanced Specificity of the Modified m168 ZZ Sindbis Pseudotyped Virus In Vitro.

[0113] A representative experiment illustrating enhanced specificity of m168 infection in 293T cells, in the presence of an HLA monoclonal antibody is shown in FIG. 5a. In the absence of antibody the background level of infectivity is reduced when compared to the ZZ SINDBIS virus and the levels of infectivity and stability are maintained. A Western blot of m168 pseudotyped virions shows the E2 envelope protein expressed from wild type ZZ SINDBIS and m168 (FIG. 5b). Note that the m168 envelope protein is larger as a result of mutation m1 that prevents cleavage of E2 and E3. This mutant was used in subsequent experiments.

m168 ZZ SINDBIS Pseudotyped Virus Displays Reduced Non-Specific Infectivity in Mice.

[0114] The ultimate goal of these studies is to develop a gene transfer vector capable of delivery directly into the bloodstream to target specific tissues or cells. The ability of the genetically modified m168 lentiviral pseudotypes to infect target cells in live mice was tested. First, we determined the level of non-specific infectivity in the absence of targeting antibody. Viruses bearing luciferase reporter genes were injected via the tail vein into SCID mice and the location of the infectivity was assessed using a CCD camera to determine the level of luciferase expression in the mice. Consistent with the in vitro results, the modified m168 ZZ SINDBIS pseudotyped virus displayed a substantially lower infectivity in the liver and spleen of inoculated animals, relative to the parental ZZ SINDBIS pseudotyped virus (FIG. 6). Because the intensity of the CCD imaging for luciferase expression can be influenced by a number of variables such as depth of tissue and positioning of the animal during imaging, we confirmed these results by isolation of organs and PCR analysis for vector DNA sequences (Table 2). These results confirm that infectivity in liver and spleen is substantially reduced. Of note, we could not detect infection in ovaries indicating that transduction of our vector into germ line cells was unlikely to occur. Having successfully reduced the background infectivity, we tested the ability of these m168 pseudotypes to target
cancer cells in the presence of monoclonal antibody directed to a tumor specific cell surface antigen, P-gp in mice. m168 Virus Specifically Targets P-gp Expressing Melanoma Cells in NOD/SCID Mice. 

MALIGAN'T MELANOMA IS AN AGGRESSIVE HUMAN TUMOR THAT METASTASIZES TO MULTIPLE TISSUES INCLUDING REMOTE SKIN, SOFT TISSUE, LYMPH NODE AND LUNG (ALLEN AND COT, CURR. OPIN. ONCOLO. 14, 221-226 (2002)). SEVERAL INTRINSIC PROPERTIES OF TUMOR CELLS CONSTITUTE THE DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPEUTIC DRUGS. INCREASED EXPRESSION OF THE MULTIDRUG-RESISTANT (MDR) GENES CAUSES OVERPRODUCTION OF THE TRANSMEMBRANE TRANSPORT PROTEIN P-gp (AMBUDKAR ET AL., ONCOGENE. 22, 7468-7485 (2003)). P-gp TRANSPORTS NEUTRAL AND CATIONIC HYDROPHILIC COMPOUNDS ACROSS THE CELL MEMBRANE. SELECTION FOR TUMOR CELLS THAT ARE RESISTANT TO NATURAL PRODUCT AMPHIPHILIC ANTAGONISTIC DRUGS CAN INDUCE EXPRESSION OF P-gp. ELEVATED LEVELS OF P-gp HAVE BEEN FOUND IN MANY SOLID TUMORS OF THE COLON, KIDNEY, LIVER AND LUNG THAT HAD NOT BEEN EXPOSED TO CHEMOTHERAPY ACCOMPANIED BY DEVELOPMENT OF THE MULTI-DRUG RESISTANCE. ONE STUDY DEMONSTRATED THAT 33 TO 76% OF THE MELANOMA CELL LINES DERIVED FROM PRIMARY TUMORS OR METASATASES OF UNTREATED PATIENTS SCORED POSITIVE FOR P-gp (BERGER ET AL., INT. J. CANCER 59, 717-723 (1994)).

[0116] We selected a murine model for human malignant metastatic melanoma where the tumor cells migrate through the bloodstream to engraft and form tumors in the lungs. We engineered the murine melanoma cells to express the human MDR1 gene (the vector is shown in FIG. 1) in order to provide a cell surface molecule for targeting. This served as our live animal model system that allowed us to stringently test whether our mutant E2 virus vector can target P-gp on the surface of the melanoma cells within live animals.

[0117] First, we demonstrated the specificity of the targeting for the P-gp expressing melanoma cells in vitro. A Firefly luciferase reporter gene was used to quantitate transduction of the melanoma cells by flow cytometry. Our results demonstrate that P-gp can be specifically targeted on the surface of the melanoma cells. In the presence of monoclonal antibody, infection of the melanoma cells is significantly greater than the original ZZ SINDHS pseudotype vector (Table 3). The P-gp transducing vector does not significantly infect cells that do not bear P-gp (data not shown). Thus, this combination of tumor cells and transducing vector was utilized for vector targeting in live mice.

TABLE 3

<table>
<thead>
<tr>
<th>Virus</th>
<th>Antibody</th>
<th>RLU</th>
<th>Vector Copy/#/10^6 cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>FULhcW (m168)</td>
<td>Anti P-Glycoprotein</td>
<td>3104</td>
<td>65</td>
</tr>
<tr>
<td>FULhcW (ZZ SINDHS)</td>
<td>Anti P-Glycoprotein</td>
<td>1834</td>
<td>77</td>
</tr>
<tr>
<td>FULhcW (ZZ SINDHS)</td>
<td>Anti P-Glycoprotein</td>
<td>415</td>
<td>19</td>
</tr>
</tbody>
</table>

*Values represent mean luciferase units and are representative of three independent experiments.

The tumor cells were first marked in vitro by transducing with a vector expressing Renilla luciferase. This allowed us to differentiate identity of location of vector expression in the tumor cells. The localization of vector expression and tumor cells in the mice was visualized using different substrates for the two luciferase genes, Firefly and Renilla, respectively (FIG. 7). Following injection, the tumor cells migrate to the lungs and can be visualized by CCCI imaging for Renilla luciferase. The virus bearing m168 and anti P-gp antibody was injected via the tail vein. Vectors injected in the absence of anti P-gp antibody show no signal for Firefly luciferase. In contrast, when virus is pseudotyped with m168 bearing anti P-Gp antibody, the luciferase expression of Firefly luciferase (m168 virus vector) co-localizes in the lung with that of Renilla luciferase (tumor melanoma cells).

[0119] The co-localization in the lungs of Firefly and Renilla luciferase expression representing tumor and virus infection, respectively, was confirmed to be a result of infection of the melanoma cells by the targeting vector. Lung tissue was isolated and melanoma cells cultured. Firefly luciferase activity, representing expression from the vector, was observed predominately in those tumor cells isolated from animals in which anti P-gp targeted virus was used for the infection (Table 3). Quantitative real time PCR analysis confirmed these results. Interestingly, m168 pseudotype vectors demonstrate a higher level of infection in melanoma cells in vivo compared to the parental ZZ SINDHS, most likely due to less nonspecific trapping in other mouse tissues.

[0120] The targeting of micrometastatic tumors was also visualized by immunohistochemistry (see, FIG. 10). Tumor micro-nodules are observed in the lungs at Day 6 following transplant with morphologic characteristics of melanoma and positive for melanoma antigen S-100. About 1% of these nodules were also positive for EGFP, consistent with the previous PCR analysis (see, Table 2 of K. Morzono et al., Nature Med (2005) 11:346-352, hereby incorporated herein by reference in its entirety for all purposes).

[0121] Rare transduced cells in the spleen and liver were identified as macrophages and related Kupffer cells, respectively, by flow cytometry and immunohistochemistry (FIGS. 11, 12a and 12b).

Targeting of Established Melanoma Tumors.

[0122] In another set of experiments, we tested the ability of the m168 vector to target established tumors. The same protocols as above were utilized except that tumors were
allowed to form for 12 days prior to intravenous injection of the targeting vector. In this model system, visible tumors are evident at 8 days after inoculation and death occurs within 16 days after inoculation. Animals were visualized by CCD imaging 3 days following intravenous injection for both the location of tumors and the specificity of targeting. Specific targeting to the tumors in the lungs of the animals was observed only following intravenous injection with m168 pseudotypes plus P-gp antibody (see, FIG. 13a). No non-specific infection was observed in the lungs in the absence of tumor and the infection to tumors in the lungs was dependent upon the presence of P-gp antibody. The transduction of organs was confirmed by isolation of specific organs following sacrifice (see FIG. 13b). The reduced signal intensity in lungs of this experiment relative to targeting of microsomatic cells (compare mice of FIG. 13a with mice of FIG. 7) is due to limited growth of transduced cells (3 days versus 12 days after transduction) prior to imaging. For comparison, intravenous injection of VSVG pseudotypes show infection of a broad number of tissues without specificity for the tumors consistent with previously published studies (Sawai and Mermelo, Biochem Biophys Res Commun (1998) 248:315-323).

Discussion

[0123] We developed a gene therapy targeting strategy that for the first time allows production of a high titer virus that can be directed to specific cells and tissues. Most importantly, the high titer and specificity of this vector system makes it suitable for applications within living animals.

[0124] We took advantage of several aspects of the Sindbis virus envelope in designing our vector system. The Sindbis envelope consists of a cell derived lipid bilayer embedded with two integral membrane glycoproteins, E1 and E2, which mediate membrane fusion and receptor binding, respectively. Following binding of E2 to its receptor and endocytosis, E1 leads to fusion in a pH dependent fashion independent of E2. E1 and E2 are anchored in the cell membrane independently via transmembrane domains; an attribute that likely accounts for the high level of envelope stability and maintenance of function in chimeric molecules. Previous studies indicated that the Sindbis virus E2 envelope protein could be modified substantially yet retain infectivity (Dubuisson and Rice, Journal of Virology 67, 3363-3374 (1993)). Sindbis virus vectors with chimeric E2 envelopes were capable of targeting cells in vitro (Ohno et al., Nat. Biotechnol. 15, 763-767 (1997)).

[0125] Although Sindbis is an RNA virus, we previously created a DNA vector expressing the Sindbis envelope and demonstrated that it could be used to express functional envelope and form pseudotypes with both the HIV-1- and MolV-based vectors (Morizono et al., J. Virol., September; 75(17): 8015-20. 75, 8016-8020 (2001)). When the Sindbis virus envelope is modified to encode the ZZ domain of protein A, monoclonal antibodies directed to cell surface antigens can be used to redirect the target specificity of the retroviral vectors. Here, we substantially modified the Sindbis E2 envelope to further increase the specificity of infectivity to a degree sufficient to achieve the high level of specificity required for in vivo infection. In such a context, the virus would encounter multiple cell types and thus, an increased potential for non-specific infectivity. Although the parental (first generation) ZZ SINDIS pseudotyped vector retains infectivity in the liver and spleen, the pseudotypes bearing modified Sindbis virus envelope show a substantially decreased level of infectivity in these organs.

[0126] Although we have not investigated the specific cellular receptors responsible for the non-specific infectivity of the parental ZZ SINDIS virus, our results indicate that background infectivity is likely due to changes within the Sindbis envelope domains and not the ZZ domain. Some of the mutations we characterized are known to abolish binding of the Sindbis virus envelope to heparin sulfate and thus, are likely responsible for the decreased non-specific infectivity and resultant enhanced selectivity of these viruses (Klimstra et al., J. Virol. 73, 6299-6306 (1999); Byrnes and Griffin, J. Virol. 74, 644-651 (2000)). The phenotypes of these mutants are consistent with a previous report that characterized the role of the heparin sulfate binding domain in non-specific transduction of a targeting adenovirus vector in mice (Smith et al., Hum. Gene Ther: 14, 777-787 (2003); Koizumi et al., J. Viral. 77, 13062-13072 (2003)). By reducing the non-specific infectivity, it was possible for us to redirect the target cell specificity of the virus to a specific human tumor cell antigen, P-gp, which is expressed on the surface of murine melanoma cells.

[0127] Once a melanoma acquires the ability to invade tissues, continue to proliferate and escape immune surveillance metastatic spread is likely to occur. Metastatic competent tumor cells migrate from the site of the primary lesion and subsequently grow at distant anatomic sites including the liver and lungs. Pulmonary metastases are the most common site of visceral metastasis with between 15% and 35% of recurrence occurring in this location (Allen and Coit, Curr. Opin. Oncol. 14, 221-226 (2002)). Only 4% of patients with pulmonary metastases survive 5 years. The murine melanoma model we chose to evaluate the specificity of our mutants mimics the progression of human melanoma to a metastatic stage often found in the lung. This system was ideal for testing specific targeting of our modified ZZ virus vectors to metastatic tumor cells by directly injecting them into the bloodstream of mice.

[0128] Targeting P-gp as a tumor antigen can be useful not only for metastatic melanoma, but for many other tumors, which express this gene and are thus rendered resistant to multiple chemotherapeutic drugs (Ambudkar et al., Oncogene, 22, 7468-7485 (2003)). However, P-gp is also expressed on some normal cells, thus the targeting of tumor cells that express P-gp would be most successful in those situations where the P-gp was significantly over-expressed in the tumor cells.

[0129] Although non-covalent interactions via the protein A ZZ domain would be useful in ex vivo applications, in an animal or patient with an immunocompetent humoral immune system, the presence of circulating antibodies would compete for the monoclonal antibodies of the targeting vector. Thus, clinical in vivo applications use chimeric, recombinant single chain antibody sequences or specific ligand and/or peptide sequences. Human choriocarcinoma gonadotropin sequences have been successfully recombined into chimeric Sindbis envelope to target Sindbis virus based vectors (Sawai and Mermelo, Biochem. Biophys. Res. Commun. 248, 315-323 (1998)). To date, we have tested these pseudotypes with over ten specific monoclonal antibodies. Any specific ligand or affinity reagent incorporated into the Sindbis envelope can be used to target a cell surface molecule specific to a given cell or tissue type.
The applications of a specific targeting gene therapy vector are broad. In the melanoma model, for example, one could introduce specific suicide genes to kill tumor cells and/or immunomodulatory genes to enhance immune response directed to metastatic lesions. Early treatment of metastatic cells is of significant therapeutic value. In theory, metastases could be targeted well before they grow to a size to be visualized by current technologies. Residual tumor cells following localized treatment with radiation and/or surgery could also be targeted and eliminated.

The targeting of gene therapy vectors to specific cells and tissues at specific sites in the body has numerous applications. Current applications of gene therapy require either ex vivo purification of cells followed by transduction of the purified target cells and/or injection directly into localized sites, both of which require extensive technical manipulation (Kohn et al., Nat. Med. 1, 1017-1023 (1995); Cavazzana-Calvo et al., Science 288, 669-672 (2000)). Direct injection into the bloodstream and injection to specified regions would facilitate the application of gene therapy to many diseases. Since most diseases, both acquired and hereditary, either originate in specific cells or manifest their clinical phenotypes in specific tissues, the gene therapeutic vectors could be delivered where they would be most effective. For example, gene therapy utilizing hematopoietic progenitor cells currently require purification of the hematopoietic stem cells followed by transduction ex vivo. Specific targeting vectors can be developed that target antigens specific for hematopoietic stem cells and thus, allow direct introduction of therapeutic genes into the stem cells through bone marrow and/or systemic injection after progenitor cell mobilization. As evidenced by our ability to target the melanoma tumor cells prior to establishment of visible tumors in the lungs, targeting vectors that circulate and home to specific cells could allow early therapeutic intervention in the case of diseases such as cancer, and residual cells of chronic or latent infections by infectious agents. This system could also be applied to treatment of pulmonary diseases such as cystic fibrosis and alpha-1 antitrypsin deficiency, caused by mutations in the CFTR (CF transmembrane conductance regulator) and alpha-1 antitrypsin genes respectively (West and Rodman, Chest 119, 613-617 (2001)). In principle, the CFTR and alpha-1 antitrypsin genes could be delivered efficiently to lung cells by a simple intravenous injection.

Finally, targeting of specific cells and tissues would greatly enhance the safety of gene therapeutic applications. Inappropriate expression due to inadvertent injection of irrelevant cells or tissues is one cause for concern in gene therapy applications and has resulted in serious adverse effects in some clinical trials (Lehman, Science 401, 517-518 (1999)). Targeting to specific cells would lessen the possibility of adverse side effects. In addition, insertional mutagenesis of the retroviral vector, if it does occur, would be limited to a much smaller subset of cells, thus diminishing the possibility of events leading to the initiation and/or progression of malignant transformation (Hacine-Bey-Ahmed et al., Science 302, 415-419 (2003)). It is important to note that this targeting system has broad applicability for use with other retroviral vectors. Although we utilized lentiviral vectors in this study, we previously demonstrated that the Sindbis ZZ pseudotypes will also from readily with MuLV vectors, more commonly utilized in most existing gene therapy clinical applications for a variety of diseases.

Example 2

Targeting Prostate Cancer Cells through the Prostate Stem Cell Antigen (PSCA)

Prostate cancer is the most common cancer diagnosis and the second leading cause of cancer-related death in American men. Prostate cancer mortality frequently results from metastasis to bone and hormone-independent tumor growth. Physiologically relevant prostate cancer models exist, such as the LAPC-9 xenograft model (see, Craft, et al., Cancer Res. 2000 60:2541-2546). LAPC-9 cells were derived from a human bone metastasis, and are able to form a prostate cancer xenograft that can be propagated in SCID mice, and expresses prostate specific antigen and wild-type androgen receptor (Id.). Hormone independent outgrowths can be selected after castration of the mice, and micrometastasis can eventually be detected in half of the mice, recapitulating the clinical progression of human prostate cancer (Klein, et al., Nature Med. 1997 3:402-408).

We generated vectors that specifically deliver genes to prostate cancer in a living animal, and validated our vectors in the LAPC-9 model system. First, we found a candidate surface molecule in prostate cancer cells that our engineered Sindbis envelopes could target. Prostate stem cell antigen (PSCA) is a prostate-specific gene with 50% homology to stem cell antigen 2, a member of the T(3/1)-Ly-6 family of glycosyolphosphatidylinositol (GPI) anchored cell surface antigens. PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites (Gu, et al., Oncogene 2000) 19:1288-96; and Reiter, et al., Proc Natl Acad Sci USA (1998) 95:1735-1740). PSCA mRNA expression is prostate-specific in normal male tissues and is highly up-regulated in both androgen-dependent and -independent prostate cancer xenografts. PSCA is expressed in over 80% of prostate cancers, among them the LAPC-9 xenograft (Saffran, et al., Proc Natl Acad Sci (2001) 98:2658-2663), and is a promising therapeutic target. Thus, we targeted Sindbis pseudotyped lentiviral vectors with an anti-PSCA mAb, 1G8 (Saffran, supra). Although PSCA is widely expressed in human prostate cancers, expression is very low or undetectable in prostate cancer cell lines. We obtained a LNCAp derivative cell line stably transfected with PSCA (R. Reiter, UCLA), LPSCA4, and analyzed the ability of 1G8 to mediate infection of FUGW (that expresses EGF from ubiquitin C promoter) pseudotyped with m168 (FIG. 14). LPSCA4 was very effectively infected by FUGW with both eHLA 1G8 antibodies, whereas the parental LNCAp cells could only be infected with eHLA. 1G8 did not mediate infection into LNCAp cells, as levels were comparable to background infection in the absence of targeting antibody.

Example 3

Combining Cell Surface Targeting with Selective Cell to Increase Efficiency of Specific Targeting


Example 4

Targeting CNS Tissue By Conjugation To Anti-Transferrin Receptor Antibody

We successfully targeted transduction of human umbilical vein endothelial cells (HUVEC) via TIR using TIR Monoclonal Antibodies. (0137) Transferrin receptor (TIR) is highly expressed on brain capillary endothelial cells and has been used by Partridge and co-workers as a means to deliver therapeutic reagents into the brain (Partridge, Neuron (2002) 36:555-558; and Partridge, Nat Rev Drug Discov (2002) 1:131-139). We determined that TIR could serve as a receptor for targeted infection by testing infection with m168 pseudotypes conjugated with antibodies directed to human TIR expressed on human umbilical vein endothelial cells (HUVEC). There are several available monoclonal antibodies directed to different or unknown epitopes of TIR (Panaccio, et al., Immunol Cell Biol (1987) 65:461-472; Esserman, et al., Blood (1989) 74:2718-2729; and Takahashi, et al., Blood (1991) 77:826-832). Our results demonstrate successful infection of HUVEC with TIR antibody, but not in the absence of TIR antibody. However the levels of infectivity were low compared to targeting to other cell surface molecules such as CD4, HLA, and P-gp in other cell types. (FIG. 16)

[0139] It was reported that a single mutation within the E1 envelope protein renders Sindbis virus replication to be independent of a requirement for cholesterol (Lu, et al., J Virol (1998) 73:4272-4278). A similar mutation was also identified in Semliki Forest virus (Vashishth, et al., J Cell Biol (1998) 140:91-99). The mechanism of this cholesterol independent replication is unclear. Since the E1 protein is responsible for fusion of Sindbis envelope to induce entry into the cell, we reasoned that this mutation in the context of our targeting vector would work in concert with antibody mediated binding to enhance the infectivity of the targeting viruses. Our results show that this is the case. Introduction of the cholesterol independent mutation (E1 AK226-227SG) into the targeting Sindbis envelope (termed 2.2) enhanced infectivity of lentiviral pseudotypes 8-fold over that of m168 pseudotypes targeted to TIR (FIG. 16). These results demonstrate that efficient targeting to TIR can be obtained in cell culture.

Targeting to the CNS in Living Mice.

[0140] Using the modified vector described above we tested its ability to target TIR, particularly TIR expressing cells of the brain capillary endothelium. Mice were injected intravenously with anti-TIR conjugated vector through the tail vein. Five (5) days after injection mice were analyzed for location of transduced cells by optical imaging for expression of the luciferase reporter gene. We observed a distribution of luciferase activity in the body consistent with successful targeting to the CNS. Intense optical signals were observed in regions corresponding to the brain and spinal column. These results were confirmed after sacrifice by removing the skin and muscle from the back of the animals confirming luciferase expression from the brain and spinal column (FIG. 17). Control mice injected with vector in the absence of TIR antibody did not show a signal in the CNS, consistent with typical control animals utilized in the experiments targeting P-gp on melanoma (Morizono, et al, supra). It is noteworthy that although TIR is expressed on multiple cells and tissues in the body (Gatter, et al., J Clin Pathol (1983) 36:539-45; Lu, et al., Acta Pathol Jpn (1989) 39:759-764; and Soyer, et al., J Cutan Pathol (1987) 14:1-5), the major sites of transduction were observed in the regions corresponding to the central nervous system. Without being bound to any theory, this may be due to a higher density of transferrin receptor and/or enhanced rates of internalization of transferrin receptor in these regions (Partridge, Neuron, supra; and Partridge, Nat Rev Drug Discov, supra).

[0141] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
<212> TYPE: DNA
<213> ORGANISM: Sindbis virus
<220> FEATURE:
<223> OTHER INFORMATION: ZZSINDIS Sindbis virus ZZ envelope protein mutant

<400> SEQUENCE: 1

atacgctgg cacacaacat ggtcagccga aatggtttcg tcggaattg tagttccoca 60
tgccagcccc gcccacactg ctataccgcc gcacctccca gaccccttga catccttgaa 120
ggaacgtgca acatgaggg cacattaccgc catttttgag tggcagaccc 180
tcttgccagaa gcacatagga acctacttgac gtcttttcc ctttaccc caacccgac 240
aactgtcgcg aaccccaaca tactgtaccc tggcctaccc gatctcaagc cacagggctc 300
tgagagcagc tggaaatggcc caccataac tttatatg ttttttcttt cttttaattg 360
caccarggac cacaatacag cagccatcgt ggtttaagaag taaaccagcc aacaagcgtc 420
aacacacttc acacaracaa ccaaaacggt tcttataag ttttttattt ctttttaacc 480
aacgatatcc aacagtccag cttattcccag agtttaaaag atcaacccaggg aacaagcgtc 540
aactttttag cagggaaata aagtactaat tgtggtccag gccgagaaag aacccgac 600
ttcacaaag cacaacaaaa cgcgtccctat gatcccttat attactcata ttaaaccgaa 660
gaacacagcc aagcctttct cccagattta aagatgaccc caacccgacg ctcatttctt 720
tttacgacag ctaaaacagtc aataagcgct cggcgccgca aagatgaccc gaatctcgcg 780
tgtttcctgc gaagagccgct tttatcaggg ctataagcga ccacccgacg ccctttgttc 840
agcacttcag caccctcgag aagttctcag ttttttcttt ctaaagggct 900
cctcagggag cccctgaacag tgtgactaag tgtgactaca actccgacac gctattgac 960
cgtgagagcc gccttaattc gagcggaa aacatgctgt cccctgtcag tatttattc 1020
cagctgaaaa aatcccttctt c cacagctgac gccgctctga aagaaacacc tacgggtcat 1080
atccctatgc aacccgcaac aacccgacct ttaacatcct actgcaagga aatcaggggc 1140
aagagttacc ccaagccgcc actggggaga aaccattagt gatggcgaag tgggaggtac 1200
tacaagccg ggacgggcat gacagcctgg aacaaactgg gtgtcacacc ccaacagcgg 1260
tggtgtcttc atagagccag ccacccgacg tggcctttca acctccgagg cttgactaga 1320
cataagagcc aacagccgga aggaaattc cattccttc ttaattgtg gcccgagttc 1380
tcgtaggtcct cttggtgcaa ccgagccgtaaatcgtgctatttcgtttaaacttctgaaacc 1440
cataagata cacaacactt gacattgctc accacccgga gactaggggc aacaccggaa 1500
ccaccctgc aatgtggtgc cggaaagagc gcgcacaaact ttacggctcga cgagatggtc 1560
cgtaatcata tattgggaatt ccacctgaaca cgtgaggtgct gctgtggccac 1620
ggccacctc aacgccgac gacccgctaactgcagcact ccacccggtg 1680
tacaagactt ctcgctgcag ctcgggttag ccagcggga ctcgtgcacc tcgtgctgtg 1740
tgttgttgtg cctgtaasaag gcccctgtgac tcagcgcctt ggcggcaccac 1800
gccoagtact ctagctgttc tttgctgttgta cgtgctggtc tgggaggaag 1860
ttattagcaga cacagttgct cttgggtgcg aacagcctgg ctttatttgt ctttattgtc 1920
tgctatcatt tcagcgcggc cttcttggctct cggctcgtctg cctcttgcctt 1980
tgctgtgtgc cggcggcct cctgctgagc gccgatcctg cagcagctgtc 2040
ccaagatgc ccaacatcag ccataaggca ctttgtggaa ggcaggtgta tgcgctggctc 2100
<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met</td>
<td>Ala</td>
<td>Ser</td>
<td>Ala</td>
<td>Ala</td>
<td>Pro</td>
<td>Leu</td>
<td>Val</td>
<td>Thr</td>
<td>Ala</td>
<td>Met</td>
<td>Cys</td>
<td>Leu</td>
<td>Leu</td>
<td>Gly</td>
<td>Ann</td>
</tr>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
<td>Phe</td>
<td>Pro</td>
<td>Cys</td>
<td>Asp</td>
<td>Arg</td>
<td>Pro</td>
<td>Pro</td>
<td>Thr</td>
<td>Cys</td>
<td>Tyr</td>
<td>Thr</td>
<td>Arg</td>
<td>Glu</td>
<td>Pro</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Arg</td>
<td>Ala</td>
<td>Leu</td>
<td>Asp</td>
<td>Ile</td>
<td>Leu</td>
<td>Glu</td>
<td>Ann</td>
<td>Val</td>
<td>Asn</td>
<td>His</td>
<td>Glu</td>
<td>Ala</td>
<td>Tyr</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Thr</td>
<td>Leu</td>
<td>Leu</td>
<td>Asn</td>
<td>Ala</td>
<td>Ile</td>
<td>Leu</td>
<td>Arg</td>
<td>Cys</td>
<td>Gly</td>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
<td>Gly</td>
<td>Arg</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lys</td>
<td>Arg</td>
<td>Ser</td>
<td>Val</td>
<td>Ile</td>
<td>Asp</td>
<td>Arg</td>
<td>Phe</td>
<td>Thr</td>
<td>Leu</td>
<td>Thr</td>
<td>Ser</td>
<td>Pro</td>
<td>Tyr</td>
<td>Leu</td>
<td>Gly</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
<td>80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Cys</td>
<td>Ser</td>
<td>Tyr</td>
<td>Cys</td>
<td>His</td>
<td>His</td>
<td>Thr</td>
<td>Val</td>
<td>Pro</td>
<td>Cys</td>
<td>Phe</td>
<td>Ser</td>
<td>Pro</td>
<td>Val</td>
<td>Lys</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Glu</td>
<td>Val</td>
<td>Trp</td>
<td>Asp</td>
<td>Glu</td>
<td>Ala</td>
<td>Asp</td>
<td>Arg</td>
<td>Ile</td>
<td>Gln</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>105</td>
<td>110</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
<td>Ala</td>
<td>Gln</td>
<td>Phe</td>
<td>Gly</td>
<td>Tyr</td>
<td>Asp</td>
<td>Gln</td>
<td>Ser</td>
<td>Gly</td>
<td>Ala</td>
<td>Ser</td>
<td>Ala</td>
<td>Ann</td>
<td>115</td>
</tr>
<tr>
<td>Residue</td>
<td>Sequence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>130</td>
<td>Lys Tyr Arg Tyr Met Ser Leu Lys Gln Val Thr Asp Asn Lys Phe Asn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>135</td>
<td>Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>Asn Glu Glu Gln Arg Asn Ala Phe Tyr Glu Ile Leu Lys Asp Asp Pro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>145</td>
<td>Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>Gln Ala Pro Lys Val Asp Asn Lys Glu Gln Gln Asn Ala</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>155</td>
<td>Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>Ala Phe Ile Glu Ser Leu Lys Asp Asp Pro Ser Glu Ser Ala Asn Leu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>165</td>
<td>Leu Ala Glu Ala Lys Leu Asn Asp Ala Glu Ala Pro Lys Val Asp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>170</td>
<td>Ala Asn Ser Ser Ser Val Pro Gly Asp Pro Val Thr Thr Val Lys Glu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>Gly Thr Met Asp Asp Ile Lys Ile Ser Thr Ser Gly Pro Cys Arg Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>Leu Ser Tyr Lys Gly Tyr Phe Leu Leu Ala Lys Cys Pro Pro Gly Asp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>185</td>
<td>Ser Val Thr Val Ser Ile Val Ser Ser Asn Ser Ala Thr Ser Cys Thr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>Leu Ala Arg Lys Ile Lys Pro Lys Phe Val Gly Arg Glu Lys Tyr Asp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>195</td>
<td>Leu Pro Pro Val His Gly Lys Ile Pro Cys Thr Val Tyr Asp Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>Leu Lys Glu Thr Thr Ala Gly Tyr Ile Thr Met His Arg Pro Arg Pro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>205</td>
<td>His Ala Tyr Thr Ser Tyr Leu Glu Glu Ser Ser Gly Lys Val Tyr Ala</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>Lys Pro Pro Ser Gly Lys Asn Ile Thr Tyr Glu Cys Lys Cys Gly Asp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>Tyr Lys Thr Gly Thr Val Ser Thr Arg Thr Glu Ile Thr Gly Cys Thr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>Ala Ile Lys Glu Cys Val Ala Tyr Lys Ser Asp Glu Lys Thr Lys Trp Val</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>Phe Asn Ser Pro Asp Leu Ile Arg His Asp Asp His Thr Ala Glu Gly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>230</td>
<td>Lys Leu His Leu Pro Phe Lys Leu Ile Pro Ser Thr Cys Met Val Pro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>235</td>
<td>Val Ala His Ala Pro Asn Val Ile His Gly Phe Lys His Ile Ser Leu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>Gln Leu Asp Thr Asp His Leu Thr Leu Leu Thr Thr Arg Arg Leu Gly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>245</td>
<td>Ala Asn Pro Glu Pro Thr Glu Trp Ile Val Gly Lys Thr Val Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>250</td>
<td>Asp Phe Thr Val Asp Asp Gly Leu Glu Tyr Ile Trp Gly Asn His</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>255</td>
<td>Glu Pro Val Arg Val Tyr Ala Glu Glu Ser Ala Pro Gly Asp Pro His</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
-continued

Gly Trp Pro His Glu Ile Val Glu His Tyr Tyr His Arg His Pro Val
545  550  555  560

Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala Met Met Ile Gly
565  570  575

Val Thr Val Ala Val Leu Cys Ala Cys Lys Ala Arg Arg Glu Cys Leu
580  585  590

Thr Pro Tyr Ala Leu Ala Pro Asn Ala Val Ile Pro Thr Ser Leu Ala
595  600  605

Leu Leu Cys Cys Val Arg Ser Ala Asn Ala Glu Thr Phe Thr Glu Thr
610  615  620

Met Ser Tyr Leu Thr Ser Asn Ser Gln Pro Phe Phe Thr Val Glu Leu
625  630  635  640

Cys Ile Pro Leu Ala Ala Phe Ile Val Leu Met Arg Cys Cys Ser Cys
645  650  655

Cys Leu Pro Phe Leu Val Val Ala Gly Ala Tyr Leu Ala Lys Val Asp
660  665  670

 Ala Tyr Glu His Ala Thr Thr Val Pro Asn Val Pro Gln Ile Pro Tyr
675  680  685

Lys Ala Leu Val Glu Arg Ala Tyr Ala Pro Leu Asn Leu Glu Ile
690  695  700

Thr Val Met Ser Ser Glu Val Leu Pro Ser Thr Asn Gln Glu Tyr Ile
705  710  715  720

Thr Cys Lys Phe Thr Thr Val Val Pro Ser Pro Lys Ile Lys Cys Cys
725  730  735

Gly Ser Leu Glu Cys Gln Pro Ala Leu His Ala Asp Tyr Thr Cys Lys
740  745  750

Val Phe Gly Gly Val Tyr Pro Phe Met Trp Gly Gly Ala Glu Cys Phe
755  760  765

Cys Asp Ser Glu Asn Ser Gln Met Ser Glu Ala Tyr Val Glu Leu Ser
770  775  780

 Ala Asp Cys Ala Ser Asp His Ala Gln Ala Ile Lys Val His Thr Ala
785  790  795  800

 Ala Met Lys Val Gly Leu Arg Ile Val Tyr Gly Asn Thr Thr Ser Phe
805  810  815

Leu Asp Val Tyr Val Asn Gly Val Thr Pro Gly Thr Ser Lys Asp Leu
820  825  830

Lys Val Ile Ala Gly Pro Ile Ser Ala Ser Phe Thr Pro Phe Asp His
835  840  845

Lys Val Val Ile His Arg Gly Leu Val Tyr Asn Tyr Asp Phe Pro Glu
850  855  860

Tyr Gly Ala Met Lys Pro Gly Ala Phe Gly Asp Ile Gln Ala Thr Ser
865  870  875  880

Leu Thr Ser Lys Asp Leu Ile Ala Ser Thr Asp Ile Arg Leu Leu Lys
885  890  895

 Pro Ser Ala Lys Asn Val His Val Pro Tyr Thr Gln Ala Ser Ser Gly
900  905  910

Phe Glu Met Trp Lys Asn Ser Gly Arg Pro Leu Gln Glu Thr Ala
915  920  925

Pro Phe Gly Cys Lys Ile Ala Val Asn Pro Leu Arg Ala Val Asp Cys
930  935  940
<210> SEQ ID NO 3  
<211> LENGTH: 3327  
<212> TYPE: DNA  
<213> ORGANISM: Sindbis virus  
<220> FEATURE:  
<223> OTHER INFORMATION: m168 Sindbis virus ZZ envelope protein mutant  
<400> SEQUENCE: 3  
atggtgtgctc tagacacgac ggctaacgga atgtatatag tcggaatgt gagctctccaa 60  
tgagagcgcc gcagcaattt gatatacctgc atcggttactg cagctctccaa 120  
gagaagcgtga cagctacgatc tcgggtcggtg cgaagtagc atcggttactg 180  
ttcgtgccag tcggttactg tcgggtcggtg cgaagtagc atcggttactg 240  
tgccgtccat cttagcatgc cttggtgccat cgggtttagt gaggctggtg 300  
gctgttttg aggagcggca cagttatcgg cagttatcgg cagttatcgg 360  
gctggtggtt tagagctttt tagagctttt tagagctttt tagagctttt 420  
agagcttata tagagctttt tagagctttt tagagctttt tagagctttt 480  
cagttatcgg cagttatcgg cagttatcgg cagttatcgg cagttatcgg 540  
gctgttttg aggagcggca cagttatcgg cagttatcgg cagttatcgg 600  
gctggtggtt tagagctttt tagagctttt tagagctttt tagagctttt 660  
gctgttttg aggagcggca cagttatcgg cagttatcgg cagttatcgg 720  
agalggggcag agagctttt tagagctttt tagagctttt tagagctttt 780  
agalggggcag agagctttt tagagctttt tagagctttt tagagctttt 840  
agalggggcag agagctttt tagagctttt tagagctttt tagagctttt 900  
agalggggcag agagctttt tagagctttt tagagctttt tagagctttt 960  
agalggggcag agagctttt tagagctttt tagagctttt tagagctttt 1020
-continued

attcctgccg cagctgtacg cgcgttggca gcaacaacctg cagctacat caacctgcac
1080
agggcgcagc cgcgccggtta tacatcctac ctgggaatct catcagggaa agttagcgca
1140
aagccgctat cttggaaagaa cattaagctt gtattgcaag ggctggcata caaagcggga
1200
acgtgttccg caaccacgca aacoagcgtg tgcacccgca tcaacagcagct cgtaggtcct
1260
aagagcagcc aacoagcgtg ggtttccacat tcacccgact tgcacagcaca tcaacccgac
1320
aagcccaacc ggaatctgca ttgtgcccttc aagttcgatcc cgagatcctcg ctaggtcccc
1380
gttgcaacc gcgagaaagt aataactggc ttttaaaca acaagctctca attagataca
1440
gacacttcga catgctcagc cagccagaga cttggccaaacc cgccgaaca caccaagctg
1500
tgctacgtcg gaaagaccgt cagaaaccttc acgctgcacc gacagtgcct ggaatacata
1560
tgggaaactc atagacccagt gcagtggtat gctggctgaa acttggtgct gttatacggtc
1620
gagatgaccc gcctgagacg ccctgagccca tcacccctgg cccacaaccgc cgtaatcctca
1680
gactgcgtgc gactcagctt gctctgtagtgcctgtagctcagcttgc
1740
tgaagaacgc ggaggtggct ggttagccgca tccagctgggc cccacaaccgc cgtaatcctc
1800
aactgcgtgc gactcagctt gctctgtagtgcctgtagctcagcttgc
1860
sgaagtcacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
1920
ccggctgctgtctctcttg cgcctgcgtgct cgcctgccctgct gcctgcgtgctgcctg
1980
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2040
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2100
actgcgtgct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2160
aactgcgtgc aaaaatccaa tgcgccgcct cctctctccac cctctctcact gcctgccgcc cagccagac
2220
actgcgtgc aaaaatccaa tgcgccgcct cctctctcact gcctgccgcc cagccagac
2280
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2340
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2400
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2460
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2520
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2580
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2640
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2700
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2760
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2820
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2880
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
2940
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3000
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3060
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3120
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3180
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3240
ccgcaacct gcctgccgcc cagccagacc gtctgcggtagctgtagctcagcttgc
3300
atagagtctg ctcagcgccg aagcagcagc gcagctgtacg cgcgttggca gcaacaacctg cagctacat caacctgcac
<210> SEQ ID NO: 4
<211> LENGTH: 1108
<212> TYPE: PRT
<213> ORGANISM: Sindbis virus
<220> FEATURE:
<223> OTHER INFORMATION: m168 Sindbis virus ZZ envelope protein mutant

<400> SEQUENCE: 4

Met Ala Ser Ala Ala Pro Leu Val Thr Ala Met Cys Leu Leu Gly Asn
1  5    10  15
Val Ser Phe Pro Cys Asp Arg Pro Pro Thr Cys Tyr Thr Arg Glu Pro
20 25    30
Ser Arg Ala Leu Asp Ile Leu Glu Glu Asn Val Asn His Glu Ala Tyr
35 40    45
Asp Thr Leu Leu Asn Ala Ile Leu Arg Cys Gly Ser Ser Gly Ser Val
50 55    60
Ile Asp Asp Phe Thr Leu Thr Ser Pro Tyr Leu Gly Thr Cys Ser Tyr
65 70    75  80
Cys His His Thr Val Pro Cys Phe Ser Pro Val Lys Ile Glu Gln Val
85 90    95
Trp Asp Glu Ala Asp Asn Thr Ile Arg Ile Gin Thr Ser Ala Gln
100 105 110
Phe Gly Tyr Asp Glu Ser Gly Ala Ser Ala Asn Lys Tyr Arg Tyr
115 120 125
Met Ala Ala Ala Val Thr Asp Asn Lys Phe Asn Lys Glu Gln Gln
130 135 140
Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Glu
145 150 155 160
Arg Asn Ala Phe Ile Gin Ser Leu Lys Asp Asp Pro Ser Gin Ser Ala
165 170 175
Asn Leu Leu Ala Glu Ala Lys Leu Asn Asp Ala Gln Ala Pro Lys
180 185 190
Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
195 200 205
Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gin
210 215 220
Ser Leu Lys Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala
225 230 235 240
Lys Lys Leu Asn Apr Ala Gin Ala Pro Lys Val Apr Ala Asn Ser
245 250 255
Ser Val Pro Gly Asp Pro Val Thr Thr Val Lys Glu Gly Thr Met Asp
260 265 270
Asp Ile Lys Ile Ser Thr Ser Gly Pro Cys Arg Arg Leu Ser Tyr Lys
275 280 285
Gly Tyr Phe Leu Leu Ala Lys Cys Pro Pro Gly Asp Ser Val Thr Val
290 295 300
Ser Ile Val Ser Ser Asn Ser Ala Thr Ser Cys Thr Leu Ala Arg Lys
305 310 315 320
Ile Lys Pro Lys Phe Val Gly Arg Glu Lys Tyr Asp Leu Pro Pro Val
325 330 335
His Gly Lys Lys Ile Pro Cys Thr Val Tyr Asp Arg Leu Ala Ala Thr
Thr Ala Gly Tyr Ile Thr Met His Arg Pro Arg Pro His Ala Tyr Thr 355 360 365
Ser Tyr Leu Glu Glu Ser Ser Gly Lys Val Tyr Ala Lys Pro Pro Ser 370 375 380
Gly Lys Asn Ile Thr Tyr Glu Cys Lys Cys Gly Asp Tyr Lys Thr Gly 385 390 395 400
Thr Val Ser Thr Arg Thr Glu Ile Thr Gly Cys Thr Ala Ile Lys Gln 405 410 415
Cys Val Ala Tyr Lys Ser Asp Glu Thr Lys Trp Val Phe Asn Ser Pro 420 425 430
Asp Leu Ile Arg His Asp Asp His Thr Ala Gin Gly Lys Leu His Leu 435 440 445
Pro Phe Lys Leu Ile Pro Ser Thr Cys Met Val Pro Val Ala His Ala 450 455 460
Pro Asn Val Ile His Gly Phe Lys His Ile Ser Leu Glu Leu Asp Thr 465 470 475 480
Asp His Leu Thr Leu Leu Thr Thr Arg Arg Leu Gly Ala Asn Pro Glu 485 490 495
Pro Thr Thr Glu Trp Ile Val Gly Lys Thr Val Arg Asn Phe Thr Val 500 505 510
Asp Arg Asp Gly Leu Glu Tyr Ile Trp Gly Asn His Glu Pro Val Arg 515 520 525
Val Tyr Ala Gin Glu Ser Ala Pro Gly Asp Pro His Gly Trp Pro His 530 535 540
Glu Ile Val Gin His Tyr Tyr His Arg His Pro Val Tyr Thr Ile Leu 545 550 555 560
Ala Val Ala Ser Ala Thr Val Ala Met Met Ile Gly Val Thr Val Ala 565 570 575
Val Leu Cys Ala Cys Lys Ala Arg Arg Glu Cys Leu Thr Pro Tyr Ala 580 585 590
Leu Ala Pro Asn Ala Val Ile Pro Thr Ser Leu Ala Leu Leu Cys Cys 595 600 605
Val Arg Ser Ala Asn Ala Glu Thr Phe Thr Glu Thr Met Ser Tyr Leu 610 615 620
Trp Ser Asn Ser Gin Pro Phe Phe Trp Val Gin Leu Cys Ile Pro Leu 625 630 635 640
Ala Ala Phe Ile Val Leu Met Arg Cys Ser Cys Ser Cys Leu Pro Phe 645 650 655
Leu Val Val Ala Gly Tyr Leu Ala Lys Val Asp Ala Tyr Glu His 660 665 670
Ala Thr Thr Val Pro Asn Val Pro Gin Ile Pro Tyr Lys Ala Leu Val 675 680 685
Glu Arg Ala Gly Tyr Ala Pro Leu Asn Leu Glu Ile Thr Val Met Ser 690 695 700
Ser Glu Val Leu Pro Ser Thr Asn Gin Glu Tyr Ile Thr Cys Lys Phe 705 710 715 720
Thr Thr Val Val Pro Ser Pro Lys Ile Lys Cys Cys Gly Ser Leu Glu 725 730 735
Cys Gln Pro Ala Ala His Ala Asp Tyr Thr Cys Lys Val Phe Gly Gly 740 745 750
Val Tyr Pro Phe Met Trp Gly Gly Ala Gin Cys Phe Cys Asp Ser Glu 755 760 765
<210> SEQ ID NO 5
<211> LENGTH: 3327
<212> TYPE: DNA
<213> ORGANISM: Sindbis virus
<220> FEATURE:
<223> OTHER INFORMATION: m168 mutant (E1 AK226-227SG) Sindbis virus ZZ envelope protein mutant, m168 with mutation in E1 domain

<400> SEQUENCE: 5

Aas Ser Gln Met Ser Glu Ala Tyr Val Glu Leu Ser Ala Asp Cys Ala
770  775  780
Ser Asp His Ala Gln Ala Ile Lys Val His Thr Ala Ala Met Lys Val
785  790  795  800
Gly Leu Arg Ile Val Tyr Gly Asn Thr Ser Phe Leu Asp Val Tyr
805  810  815
Val Asn Gly Val Thr Pro Gly Thr Ser Lys Asp Leu Lys Val Ile Ala
820  825  830
Gly Pro Ile Ser Ala Ser Phe Thr Pro Phe Asp His Lys Val Val Ile
835  840  845
His Arg Gly Leu Val Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Met
850  855  860
Lys Pro Gly Ala Phe Gly Asp Ile Gln Ala Thr Ser Leu Thr Ser Lys
865  870  875  880
Asp Leu Ile Ala Ser Thr Asp Arg Leu Leu Lys Pro Ser Alaa Lys
885  890  895
Asn Val His Val Pro Tyr Thr Gin Ala Ser Ser Gly Phe Glu Met Trp
900  905  910
Lys Asn Asn Ser Gly Arg Pro Leu Gin Glu Thr Ala Pro Phe Gly Cys
915  920  925
Lys Ile Ala Val Asn Pro Leu Arg Ala Val Asp Cys Ser Tyr Gly Asn
930  935  940
Ile Pro Ile Ser Ile Asp Ile Pro Asn Ala Ala Phe Ile Arg Thr Ser
945  950  955  960
Asp Ala Pro Leu Val Ser Thr Val Lys Cys Glu Val Ser Glu Cys Thr
965  970  975
Tyr Ser Ala Asp Phe Gly Gly Met Ala Thr Leu Gin Tyr Val Ser Asp
980  985  990
Arg Glu Gly Gin Cys Pro Val His Ser His Ser Ser Thr Ala Thr Leu
995  1000  1005
Gln Glu Ser Thr Val His Val Leu Glu Lys Gly Ala Val Thr Val His
1010  1015  1020
Phe Ser Thr Ala Ser Pro Gin Ala Asn Phe Ile Val Ser Leu Cys Gly
1025  1030  1035  1040
Lys Lys Thr Thr Cys Asp Ala Glu Cys Lys Pro Pro Ala Asp His Ile
1045  1050  1055
Val Ser Thr Pro His Lys Asn Asp Gin Glu Phe Gin Ala Ala Ile Ser
1060  1065  1070
Lys Thr Ser Trp Ser Trp Leu Phe Ala Leu Phe Gly Gly Ala Ser Ser
1075  1080  1085
Leu Leu Ile Ile Gly Leu Met Ile Phe Ala Cys Ser Met Met Leu Thr
1090  1095  1100
Ser Thr Arg Arg
1105
atgctctcag cagcaacact ggaacggca atggtttgc tagaataag tggcttcgca 60
tgagcagcgc cggcccaact ctaaaacctc gaaacctcc gacacccgca catccctggaa 120
gaaacagctta acatcgagc ctacagatac ctgctcaagt ccaatttgac gtgcggatcg 180
tcttgagccct tcattagcgc occatttacg accagcccc tctttgagcc atgctcgac 240
ttgcaactata ctgtagctgg ctctagcccc cttaagatcg aagcttatct gaggca aggag 300
gagctataac cctacaacat acacagtctc ccacagtctg tagtacgagc aagacgagca 360
gctgagcaaa gaaaacagcc atgctatgg gcctgagggg ttcacgacct cctcaac 420
aaaagcaagc aacatagcg ggtgagggag ccaagagtct aaccaaatgt caaaccggag 480
cgaacagcct tcctccaaag ttacaagatc gacacccgca aaagcttact tcttttcgac 540
gagctataac agttaaagtg cgctcaggg ccagagacac ccagaaatgt ccgagcagaa 600
cacaaacacg cgatcatagta gatctacatc ttactaact caaagaggaa aacagcaaac 660
gctctatac acacggtaa aagtgaggca agoaacacgc ctaaccccc ctgagaaagct 720
aaacagctaa atgagctcaag gcctggccgc gaaagcgcgca tgaagcggga ctgcgctggc 780
gacggcctaa ccacgcttac aagagacca atagctagca ctgagcagcagg ccttacggag 840
cggctgagac ggctgctact caagagacac ttttctctcg ccaaatgcct cccagcggac 900
aggttaaaggg ttaagcattg agagctagac tgagcagcagc ctgctacact ggcgcggcag 960
ataaaaacag gctgctgcag cccgctttcg caaagctgct ctgctgccag cggtaaaaa 1020
atcctgctca cagctgctac ccgcttgcgc gcaaaatcag cggcctact catctgacac 1080
agcgcacagc cgcaacgctta tacaatctac ctcgaagaca ctaacgccg aagtttcagca 1140
aagcgcacac gttgagggag ccaagagtct aaccaaatgt caaaccggag 1200
acgctttaga cccgcacagc aacaccgctgc tgcagcgcgc ctaacgccg aagtttcagca 1260
aagcgcagacc caaaagctt ggtttctaac ccacccgagc ctgctagaca tgacaggac 1320
agcgccatag ggaattagcg ttgcttcttc aagtggact cgggtacgct catctgccga 1380
gttgagcascii gcgcgagctt aatcaggtgc tttacacca cagcgtccca attagatac 1440
gacaacctca aatgggtaac cccaggggca caagagcacc aacaaacttca 1500
tggctctcgc gggagagcct cagaaacact ctcgctagct acctggcacttg atgcctttct 1560
tggagcttca atggcagcat gagggttatc gccaaagagc cagcgtcacg cagacccgc 1620
ggagcttcagc aagaaagagt acagcattac taccagcctc atgatgtgta cacoactttc 1680
gccgtctctac ctgctgtacg ggtggtcgtt ctcgctgtaa ctttgcctct gttatgtgcc 1740
tgtaaagcgc ggcgtgatgt cctgacgct ctcaggggct ccccaacacgc ctgtaaccc 1800
actggcttgc cactctttcg tggggttggg ttcagcttgat catcactttg 1860
aagtctactt tgggtgcagc gaaatctggc ttcttgggg ttcagctttg cctacactttg 1920
gccgctctg cgctcctaat gcggctcttg gcccgcgctcc ggcttttttt actggtttggc 1980
gggacgccac gtcgacagc agtcgctcgc cccactgcttc cctaatctga 2040
ctgatacgct atagcaaactc tttgataagc ctgcttatag ccctcctgca tttgagatac 2100
actgtcactt ctggtgggtt tttgctcccc aaaaacagag agaagatctc atgaaacctt 2160
accactgtggt tctctctcccc aaaaatcaca tgtgctcggt cccttggaatg ctaacgccg 2220
gtctcagcag aactactgct caaggtcctc ggggggtctg acccttttat gtttgagag 2280
---continued---

gcgcataagg tgtgcaaacag cgggcaacgc cggagagtag aggctgactg cgaattgctc
2340
gcgaaatcgc agcgggtgca cgtctgacca ccggacagcg ... 
2400

ggactgctta tgtgtaaagg gaaactacag aggttcctag atgtgtaaag ggagggagtc
2460

acacacggag ccggctaaagagcgaccagcgc ccggcgaaccgaccgctgac
2520

caacattgca aatgaagcttg tgtcctgggtg cgcattgac ccgtacggcag cccggcacaag
2580

tgtgagaccg tgaacaccagg agcgtgtgcaga cgcgtgcccc ccggcacaag
2640

gactccctcg ccgacgacgg cctagggta ctcaagccct ctcgggggaa cgtgcgatgc
2700
cgtaccacgc agggctcacta aagggtagtg atggggaaaa aacaacggaggccacactg
2760

caggaccacgc aacggttcgg ggtgaagatt tcgaagagtc cggacagcag cgggtggtgtg
2820
tcatacgagca ccattgcaaat ccggattgcgc ggtgaattt tactaattt ctaggtcatac
2880

gactgaggcgc tcgtctgaca acgtgaaatt ggaattgcta gtagcactta ttcaagcagc
2940
tccgctgggaa tcggcagccgc gcatgatgc ctccgacgat cccgtcagtc cccgcaatcc
3000
tcgccattgaa aacggcgctg cccggcctgg tctgcccacg ccgggccagcc gcggcgcgccc
3060
gtcaagtcg cttccacac ccgctgctag cggggttact ccggttgaag cggggttact
3120

agaagacaga catgcaagag gggggggtc cggcagctag cggggtttact ccggttgaag cggggttact
3180
caccaaatgc accagaaatg ctaccccagc ccggggtttact ccggttgaag cggggttact
3240
gcggctgctcg ggggttact ccggttgaag cggggttact ccggttgaag cggggttact
3300

atgatgtag atgacacacgc agagatag
3327

<210> SEQ ID NO 6
<211> LENGTH: 1108
<212> TYPE: PRT
<213> ORGANISM: Sindbis virus
<220> FEATURE:
<223> OTHER INFORMATION: m168 mutant [AJ AK226-227SG] Sindbis virus ZZ envelope protein mutant, m168 with mutation in ZZ domain

<400> SEQUENCE: 6

Met Ala Ser Ala Ala Pro Leu Val Thr Ala Met Cys Leu Leu Gly Aaa 1 5 10 15

Val Ser Phe Pro Cys Asp Arg Pro Pro Thr Cys Tyr Thr Arg Glu Pro 20 25 30

Ser Arg Ala Leu Asp Ile Leu Glu Gln Aaa Val Aaa His Glu Ala Tyr 35 40 45

Asp Thr Leu Leu Aaa Ala Ile Leu Arg Cys Gly Ser Ser Gly Ser Val 50 55 60

Ile Asp Arg Phe Thr Leu Thr Ser Pro Tyr Leu Gly Thr Cys Ser Tyr 65 70 75 80

Cys His His Thr Val Pro Cys Phe Ser Pro Val Val Lys Ile Glu Gln Val 85 90 95

Trp Asp Glu Ala Asp Aaa Thr Ile Arg Ile Glu Thr Ser Ala Glu 100 105 110

Phe Gly Tyr Asp Glu Ser Gly Ala Ser Ala Aaa Lys Tyr Arg Tyr 115 120 125

Met Ala Ala Ala Val Thr Aaa Aaa Lys Phe Aaa Lys Glu Gln Glu Gln 130 135 140

Aaa Ala Phe Tyr Glu Ile His Leu Pro Aaa Leu Aaa Glu Glu Glu Glu Glu Glu Glu 145 150 155 160
Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala 165 170 175
Asn Leu Leu Ala Glu Ala Lys Leu Asn Asp Ala Gln Ala Pro Lys 180 185 190
Val Asp Asn Lys Phe Asn Lys Glu Gin Gin Asn Ala Phe Tyr Glu Ile 195 200 205
Leu His Leu Pro Asn Leu Asn Glu Gin Gin Arg Asn Ala Phe Ile Gln 210 215 220
Ser Leu Lys Asp Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala 225 230 235 240
Lys Lys Leu Asn Asp Ala Gin Ala Pro Lys Val Asp Ala Asn Ser Ser 245 250 255
Ser Val Pro Gly Asp Pro Val Thr Thr Val Lys Glu Gly Thr Met Asp 260 265 270
Asp Ile Lys Ile Ser Thr Ser Gly Pro Cys Arg Arg Leu Ser Tyr Lys 275 280 285
Gly Tyr Phe Leu Leu Ala Lys Pro Pro Gly Asp Ser Val Thr Val 290 295 300
Ser Ile Val Ser Ser Asn Ser Ala Thr Ser Cys Thr Leu Ala Arg Lys 305 310 315 320
Ile Lys Pro Lys Phe Val Gly Arg Glu Lys Tyr Asp Leu Pro Pro Val 325 330 335
His Gly Lys Lys Ile Pro Cys Thr Val Tyr Asp Arg Leu Ala Ala Thr 340 345 350
Thr Ala Gly Tyr Ile Thr Met His Arg Pro Arg Pro His Ala Tyr Thr 355 360 365
Ser Tyr Leu Glu Glu Ser Ser Gly Lys Val Tyr Ala Lys Pro Pro Ser 370 375 380
Gly Lys Asn Ile Thr Tyr Glu Cys Lys Cys Gly Asp Tyr Lys Thr Gly 385 390 395 400
Thr Val Ser Thr Arg Thr Glu Ile Thr Gly Cys Thr Ala Ile Lys Gin 405 410 415
Cys Val Ala Tyr Lys Ser Asp Glu Thr Lys Trp Val Phe Asn Ser Pro 420 425 430
Asp Leu Ile Arg His Asp Asp His Thr Ala Gin Gly Lys Leu His Leu 435 440 445
Pro Phe Lys Leu Ile Pro Ser Thr Cys Met Val Pro Val Ala His Ala 450 455 460
Pro Asn Val Ile His Gly Phe Lys His Ile Ser Leu Gin Leu Asp Thr 465 470 475 480
Asp His Leu Thr Leu Thr Thr Arg Arg Leu Gly Ala Asn Pro Glu 485 490 495
Pro Thr Thr Glu Trp Ile Val Gly Lys Thr Val Arg Asn Phe Thr Val 500 505 510
Asp Arg Asp Gly Leu Glu Tyr Ile Trp Gly Asn His Glu Pro Val Arg 515 520 525
Val Tyr Ala Gln Glu Ser Ala Pro Gly Asp Pro His Gly Trp Pro His 530 535 540
Glu Ile Val Glu His Tyr Tyr His Arg His Pro Val Tyr Thr Ile Leu 545 550 555 560
Ala Val Ala Ser Ala Thr Val Ala Met Met Ile Gly Val Thr Val Ala 565 570 575
Val Leu Cys Ala Cys Lys Ala Arg Arg Glu Cys Leu Thr Pro Tyr Ala
580 585 590
Leu Ala Pro Asn Ala Val Ile Pro Thr Ser Leu Ala Leu Leu Cys Cys
595 600 605
Val Arg Ser Ala Asn Ala Glu Thr Phe Thr Glu Thr Met Ser Tyr Leu
610 615 620
Trp Ser Asn Ser Gln Pro Phe Phe Trp Val Gln Leu Cys Ile Pro Leu
625 630 635 640
Ala Ala Phe Ile Val Leu Met Arg Cys Cys Ser Cys Cys Leu Pro Phe
645 650 655
Leu Val Val Val Gly Ala Tyr Leu Ala Lys Val Asp Ala Tyr Glu His
660 665 670
Ala Thr Thr Val Pro Asn Val Pro Gln Ile Pro Tyr Lys Ala Leu Val
675 680 685
Glu Arg Ala Gly Tyr Ala Pro Leu Asn Leu Glu Ile Thr Val Met Ser
690 695 700
Ser Glu Val Leu Pro Ser Thr Asn Gln Glu Tyr Ile Thr Cys Lys Phe
705 710 715 720
Thr Thr Val Val Pro Ser Pro Lys Ile Lys Cys Cys Gly Ser Leu Glu
725 730 735
Cys Gin Pro Ala Ala His Ala Asp Tyr Thr Cys Lys Val Phe Gly Gly
740 745 750
Val Tyr Pro Phe Met Trp Gly Lys Ala Gin Cys Phe Cys Asp Ser Glu
755 760 765
Asn Ser Gln Met Ser Glu Ala Tyr Val Glu Leu Ser Ala Asp Cys Ala
770 775 780
Ser Asp His Ala Gin Ala Ile Lys Val His Thr Ala Ala Met Lys Val
785 790 795 800
Gly Leu Arg Ile Val Tyr Gly Asn Thr Thr Ser Phe Leu Asp Val Tyr
805 810 815
Val Asn Gly Val Thr Pro Gly Thr Ser Lys Asp Leu Lys Val Ile Ala
820 825 830
Gly Pro Ile Ser Ala Ser Phe Thr Pro Phe Asp His Lys Val Val Ile
835 840 845
His Arg Gly Leu Val Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Met
850 855 860
Lys Pro Gly Ala Phe Gly Asp Ile Gin Ala Thr Ser Leu Thr Ser Lys
865 870 875 880
Asp Leu Ile Ala Ser Thr Asp Leu Leu Lys Pro Ser Ser Gly
895 890 895
Asn Val His Val Pro Tyr Thr Gin Ala Ser Ser Gly Phe Glu Met Trp
900 905 910
Lys Asn Asn Ser Gly Arg Pro Leu Gin Glu Thr Ala Pro Phe Gly Cys
915 920 925
Lys Ile Ala Val Asn Pro Leu Arg Ala Val Asp Cys Ser Tyr Gly Asn
930 935 940
Ile Pro Ile Ser Ile Asp Ile Pro Asn Ala Ala Phe Ile Arg Thr Ser
945 950 955 960
Asp Ala Pro Leu Val Ser Thr Val Lys Cys Glu Val Ser Glu Cys Thr
965 970 975
Tyr Ser Ala Asp Phe Gly Gly Met Ala Thr Leu Gin Tyr Val Ser Asp
-continued

980 Arg Glu Gly Gln Cys Pro Val His Ser His Ser Ser Thr Ala Thr Leu
985 1000 1005
990 Gln Glu Ser Thr Val His Val Leu Glu Lys Gly Ala Val Thr Val His
995 1010 1015 1020
1000 Phe Ser Thr Ala Ser Pro Gln Ala Asn Phe Ile Val Ser Leu Cys Gly
1005 1030 1035 1040
1005 Lys Lys Thr Thr Cys Asn Ala Glu Cys Lys Pro Pro Ala Asp His Ile
1045 1060 1065 1070
1045 Val Ser Thr Pro His Lys Asn Asp Gln Glu Phe Gln Ala Ala Ile Ser
1045 1060 1065 1070
1050 Lys Thr Ser Trp Ser Trp Leu Phe Ala Leu Phe Gly Gly Ala Ser Ser
1075 1080 1085
1050 Leu Leu Ile Ile Gly Leu Met Ile Phe Ala Cys Ser Met Met Leu Thr
1090 1095 1100
1105 Ser Thr Arg Arg

<210> SEQ ID NO 7
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: m168 sequence modified for mutant (E1 AS226-227SG) Sindbis virus E2 envelope protein mutant, m168 with mutation in E1 domain

<400> SEQUENCE: 7
aagcttcctc ccag
15

<210> SEQ ID NO 9
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: m168 sequence modified in mutant (E1 AS226-227SG) Sindbis virus E2 envelope protein mutant, m168 with mutation in E1 domain

<400> SEQUENCE: 8
aagcttcctc ccag
15

<210> SEQ ID NO 9
<211> LENGTH: 9
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic integrin binding sequence "4C-RGD"

<400> SEQUENCE: 9
Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> SEQ ID NO 10
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic integrin binding sequence "4C-RGD"
<400> SEQUENCE: 10

tgcagactga gaggcgactg tttctgc 27

<210> SEQ ID NO 11
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
transferrin receptor targeting sequence "B6"

<400> SEQUENCE: 11

Gly His Lys Ala Lys Gly Pro Arg Lys
1  5

<210> SEQ ID NO 12
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
transferrin receptor targeting sequence "B6"

<400> SEQUENCE: 12

ggacaactaagtcaaggggttcc tagaaag 27

<210> SEQ ID NO 13
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Fluc-a PCR
primer for analysis of vector copy number (Firefly Luciferase)

<400> SEQUENCE: 13

ggatacgcc ctggtctctg 20

<210> SEQ ID NO 14
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Fluc-b PCR
primer for analysis of vector copy number (Firefly Luciferase)

<400> SEQUENCE: 14

gcatagcaag attctgagtac 23

<210> SEQ ID NO 15
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: beta-actin-F
PCR primer for analysis of cell number (mouse beta actin)

<400> SEQUENCE: 15

ciaactcaat atgaagtgtgac 22

<210> SEQ ID NO 16
<211> LENGTH: 21
<212> TYPE: DNA
What is claimed is:
1. A pseudotyped, targeted retroviral vector comprising:
a) a mutated Sindbis envelope comprising Sindbis envelope proteins E1, E2, and E3, wherein at least one of E1, E2, or E3 is mutated as compared to a wild-type sequence;
b) a targeting moiety linked to the Sindbis envelope.
2. The vector of claim 1, further comprising a retroviral-based nucleic acid genome.
3. The vector of claim 1, wherein the vector nucleic acid comprises a heterologous gene operably linked to a promoter.
4. The vector of claim 3, wherein the promoter is a tissue-specific promoter.
5. The vector of claim 4, wherein the tissue-specific promoter is a PSE-BC promoter.
6. The vector of claim 1, wherein the targeting moiety specifically binds to a target protein selected from the group consisting of P-glycoprotein, Her2/Neu, erythropoietin (EPO), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), cadherin, c-Jun, c-myc, c-fos, c-kit, HLA-A, HLA-B, HLA-C, chemokine receptor 5 (CCR5), stem cell marker ABCG2 transporter, ovarian cancer antigen CA125, an integrin, prostate specific antigen (PSA), prostate stem cell antigen (PSCA), dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), thyroglobulin, granulocyte-macrophage colony stimulating factor (GM CSF), myogenic differentiation promoting factor-1 (MyoD-1), Leu-7 (CD57), LeuM-1, cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 (Ki-67), HIV gp120, and transferrin receptor.
7. The vector of claim 6, wherein the targeting moiety is an antibody.
8. The vector of claim 7, wherein the targeting moiety is an antibody directed against prostate stem cell antigen (PSCA).
9. The vector of claim 7, wherein the targeting moiety is an antibody directed against P-glycoprotein (P-gp).
10. The vector of claim 7, wherein the targeting moiety is an antibody directed against a transferrin receptor.
11. The vector of claim 7, wherein the targeting moiety is covalently linked to the Sindbis envelope.
12. The vector of claim 1, wherein the targeting moiety is covalently linked to the Sindbis envelope.
13. The vector of claim 1, wherein the targeting moiety is covalently linked to the E2 or the E3 protein of the Sindbis envelope.
14. The vector of claim 1, wherein the targeting moiety is non-covalently linked to the E2 or the E3 protein of the Sindbis envelope.
15. The vector of claim 14, wherein the targeting moiety is non-covalently linked to the E2 protein Sindbis envelope via the ZZ domain of protein A.
16. The vector of claim 1, wherein E2 protein is mutated at one amino acid position.
17. The vector of claim 1, wherein E2 protein is mutated at one amino acid position.
18. The vector of claim 1, wherein E3 protein is mutated at one amino acid position.
19. The vector of claim 1, wherein E3 protein is mutated at two or more amino acid positions.
20. The vector of claim 1, wherein the mutated Sindbis envelope is encoded by a sequence listed in Table 1.
21. The vector of claim 1, wherein the mutated Sindbis envelope is encoded by m168 which has a mutation in Sindbis virus envelope protein E2.
22. The vector of claim 21, further comprising a mutation in Sindbis envelope protein E1.
23. A packaging system comprising a cell comprising nucleic acids encoding the pseudotyped, targeted retroviral vector of claim 1.
24. A packaging system of claim 23, wherein the vector further comprises a retroviral-based nucleic acid genome.
25. The packaging system of claim 24, wherein the Sindbis envelope proteins E1, E2, and E3 and the retroviral-based nucleic acid genome are encoded on the same nucleic acid.
26. The packaging cell of claim 24, wherein the Sindbis envelope proteins E1, E2, and E3 and the retroviral-based nucleic acid genome are encoded on separate nucleic acids.
27. An expression vector comprising a nucleic acid encoding Sindbis envelope proteins E1, E2, and E3, wherein at least one of E1, E2, or E3 is mutated as compared to a wild-type sequence.
28. A method of making the pseudotyped, targeted retroviral vector of claim 1, the method comprising the step of expressing in a cell a nucleic acid comprising Sindbis envelope proteins E1, E2, and E3.
37. The method of claim 33, wherein the cells are transduced in vitro.
38. A method of treating or preventing a disease state, the method comprising the step of contacting a cell with the pseudotyped, targeted retroviral vector of claim 1.
39. The method of claim 38, wherein the cell is contacted in vivo.
40. The method of claim 38, wherein the cell is contacted ex vivo.
41. The method of claim 38, wherein the cell is contacted in vitro.
42. A method of diagnosing a disease state, the method comprising the step of contacting a cell with the pseudotyped, targeted retroviral vector of claim 1.
43. The method of claim 42, wherein the cell is contacted in vivo.
44. The method of claim 42, wherein the cell is contacted ex vivo.
45. The method of claim 42, wherein the cell is contacted in vitro.
46. A method of delivering a pseudotyped, targeted retroviral vector across the blood brain barrier in a subject, the method comprising the step of contacting a cell with the pseudotyped, targeted retroviral vector of claim 10.

* * * * *